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CHAPTER I 
 
BACKGROUND 
 
Introduction 
Human Immunodeficiency Virus Type 1 (HIV-1) infection is the cause of 
Acquired Immune Deficiency Syndrome (AIDS), a major source of morbidity and 
mortality worldwide. The ability of HIV to subvert natural human immune defenses has 
contributed highly to its success in infecting the over 40 million people globally who are 
currently living with the virus.  Even more alarming is that since the discovery of AIDS 
in 1979, it has claimed the lives of over 30 million people. Fortunately, the development 
and use of Highly Active Anti-Retroviral Therapy (HAART) has significantly increased 
the life expectancy for a newly diagnosed HIV-1 patient from 8 years in 1980 to over 20 
years in 2005 (62, 122). However, recent statistics demonstrate that efforts to curb the 
growing AIDS pandemic are only just beginning. In 2005 alone, 5 million people were 
newly infected with HIV-1 and 3 million deaths were reported. In addition, the number of 
infected people has been steadily rising with the greatest increases occurring in Sub-
Saharan Africa and Asia. Therefore, while some advances have been made in the area of 
drug development, it is clear from these reports that in many ways, the struggle with 
HIV-1 is only just beginning (186). 
The history surrounding the development of new retroviral inhibitors is a story 
that highlights the profound and vital role that basic research can play in improving 
human suffering at the bedside. The HIV-1 protease was first cloned and expressed by 
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Christine Debouck and colleagues as described in a 1987 basic science communication 
(45). Based on comparisons with known retroviruses and the results of her experiments, 
Debouck speculated that her work would pave the way for the development of a new 
class of anti-retrovirals that inhibited particle maturation and therefore lead to the 
production of non-infectious, replication deficient virions. The studies published by 
Debouck and colleagues led to the opening of a new field of research with a flurry of 
several hundred basic science papers on the subject. Furthermore, these were also 
followed by the release of the first HIV-1 protease inhibitor, Amprenavir, by Glaxo 
Wellcome Inc. in 1999. HAART, which involves combined use of combinations of 
potent HIV-1 inhibitors to prevent the emergence of drug-resistant virus mutants, has 
since revolutionized the treatment of HIV, and has resulted in greatly enhanced survival 
for those with access to these valuable medications. Despite this success, drug toxicities 
and viral resistance often limit the long-term therapeutic success. Additional targets for 
antiretroviral therapy are therefore being actively investigated. It is within this model of 
bench-to-bedside science that the studies described in this thesis gain their significance. 
Presently, an understanding of the cellular and molecular events occurring during 
viral protein trafficking, viral RNA trafficking, and particle assembly is unclear. 
Particularly, the role that viral RNA plays in recruiting cellular retroviral inhibitors, and 
the extent of viral protein involvement in retroviral genomic RNA trafficking, require 
further study. Therefore, a detailed understanding of these events at the molecular and 
cellular level will facilitate the future development of inhibitors to specific steps in the 
viral life cycle, thus helping to curb the HIV pandemic at the global level. 
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AIDS History 
 In 1981, reports started to emerge describing homosexual men in America who 
were severely immuno-suppressed and therefore could not fight off infections from 
normally non-pathogenic organisms. These reports also described rare opportunistic 
infections found only in immunosuppressed individuals such as Pneumocystis carinii 
pneumonia (86) and Kaposi sarcoma (KS) (57). It was believed at the time that this 
disease was confined to the homosexual population and therefore given the name Gay 
Related Immunodeficiency Disease (GRID). Soon, groups of Haitians, intravenous drug 
users, and hemophiliacs began showing symptoms of the disease. Finally, two years after 
the first homosexual cases emerged, the Centers for Disease Control (CDC) reported the 
first case of heterosexual transmission in 1983. As a result the disease was renamed 
Acquired Immune Deficiency Syndrome or AIDS. While a cluster of symptoms had been 
assigned this name, the causative agent of this syndrome had not yet been identified 
(132). 
 Retroviruses were first suspected as the causative agent of AIDS when three 
separate laboratories isolated three separate retroviruses from AIDS patients. In 1983 in 
France, Lymphadenopathy Associated Virus (LAV) was isolated from the lymph node of 
a patient with AIDS as a collaborative effort between the laboratories of Jean-Claude 
Chermann and Luc Montagnier (3). In 1984, similar retroviruses were isolated from 
AIDS patients in the labs of Jay Levy at the University of California San Francisco and 
Robert Gallo at the National Institutes of Health (NIH). These retroviruses were called 
Human T-Lymphotropic Virus type III (HTLV-3) by the Levy group and AIDS Related 
Virus (ARV) by the Gallo group (123, 175). All three viruses were shown to be similar in 
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virion morphology to other lentiviruses by electron microscopy and were thus renamed 
Human Immunodeficiency Virus 1 (HIV-1) (97, 125, 160). It is interesting to note that 
since the discovery of HIV-1, corpses dating as far back as 1959 in China have been 
discovered to contain the virus (207). This verifies that HIV was circulating in human 
populations at least 20 years before its official discovery in 1983. 
 
History of Retroviruses 
 The Retroviridae family of viruses exhibits a unique and fascinating replication 
strategy that involves converting their RNA genome to a DNA genome using an enzyme 
called reverse transcriptase (RT). This activity is contrary to all other organisms that use 
DNA to store genetic information and RNA to transport that information to ribosomes 
and serve as a template for protein synthesis. As a result, in all other organisms genetic 
information always flows from DNA to RNA to proteins. Even other RNA viruses use 
their RNA as a template for protein synthesis and direct RNA genome replication, thus, 
preserving this central dogma of cellular molecular biology. The name “retro” therefore 
comes from the fact that during one part of the retroviral life cycle genetic information 
flows in reverse, from RNA to DNA.  
The first retroviruses, discovered in the early 20th century, were Avian Leukosis 
Virus (ALV) and Rous Sarcoma Virus (RSV). Vilhelm Ellermann and Oluf Bang 
discovered ALV in 1908 while Peyton Rous discovered RSV in 1911. Both are C type 
retroviruses discovered because of their ability to cause tumors in chickens. The 
discovery of these oncoretroviruses led to the development of the oncogene theory of 
cancer formation which became very important to the field of cancer biology. This theory 
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states that genes (called oncogenes) within some retroviruses actually cause cells to 
become cancerous or can influence certain cellular genes (also called oncogenes) to make 
a cell cancerous. Other retroviruses were discovered, many of which did not cause 
tumors, but some of which took a long time to cause disease. These “slow” viruses were 
called lentiviruses and include viruses like Bovine Immunodefficiency Virus (BIV), 
Simian Immunodefficiency Virus (SIV), Feline Immunodefficiency Virus (FIV), HIV-1 
and 2. To date, seven genera of retroviruses have been categorized: 
1. Mammalian type B retroviruses, example: mouse mammary tumor virus 
2. Mammalian type C retroviruses, example: Moloney murine leukemia virus 
3. Avian type C retroviruses, example: Rous sarcoma virus 
4. Mammalian type D retroviruses, example: Mason-Pfizer monkey virus 
5. HTLV/BLV-type retroviruses, example: human T-cell leukemia virus 
6. Lentiviruses, example: human immunodeficiency virus 
7. Spumaviruses, example: human foamy virus 
 
Lentiviruses: Properties and Classification 
 Lentiviruses are a genus of retroviruses that contain three defining features. First, 
the morphology of the internal virion structure determined by electron microscopy has an 
unusual cylindrical or cone-shaped core in the mature virus particle. Secondly, they 
encode several accessory genes that are not present in other retroviral genomes.  Lastly, 
lentiviruses are defined by a biphasic course of viral gene expression. The diseases 
caused by lentiviruses are characterized by long and variable incubation periods, 
persistent viral replication, neurological manifestations, and destruction of specific 
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hematologic or immunologic cells (49). HIVs and SIVs comprise the primate 
lentiviruses. They are all closely related, encode six accessory genes (tat, rev, nef, vpr, 
vif, and vpu, or vpx depicted in Figure 2A), and infect cells using CD4 as the primary cell 
surface receptor. HIV-2 is less prevalent than HIV-1 and is found predominantly in 
Guinea Bissau, Ivory Coast, and Senegal. There are two major subgroups of HIV-1; 
group M or main group and group O or outgroup with SIVcpz (chimpanzee) viruses 
clustering midway between them. Group O is rare and originally found only in 
Camaroon, Gabon, and France. Group M, however, is responsible for most HIV-1 cases 
and eight clades have been found (A through H) that cluster by geographic region. For 
instance, clade B is most prevalent in North America and Europe, clade E is common in 
northern Thailand, while a variety of clades is found in Africa. As a result, the majority 
of scientific studies of HIV utilize HIV-1 as the most clinically relevant virus (35). 
 
HIV-1 Pathogenesis 
 HIV-1 is transmitted by sexual contact, by blood products, or vertically from 
mother to infant. Free and cell-associated virus is found in semen, vaginal fluids, blood, 
and breast milk (64). Infection follows three phases: Acute infection, clinical latency, and 
AIDS. The typical course of HIV infection is depicted in figure 1, which was modified 
from Pantaleo et al. 1993 (152). HIV infects hematopoietic cells expressing the viral 
receptor, CD4 (42). Initial engagement of the viral attachment glycoprotein, gp120, to the 
CD4 receptor is followed by a second interaction with one of two co-receptors, CCR5 or 
CXCR4 (2, 28, 46, 56, 66). Infection initiates the acute phase which is characterized by 
an acute mononucleosis-like illness which lasts for 3-6 weeks (184). An intense burst of 
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viremia, accompanied by a drop in CD4+ cells, peaks at 6 weeks post infection (30, 40, 
77). Around this same 3-6 week period post-infection, antiviral immune responses can be 
detected that coincide with the ensuing decline in viremia and illness (103). This antiviral 
response is in the form of HIV-specific CD8+ cytolytic T lymphocytes (CTL) (116). Ten 
weeks post infection, antiviral cell mediated immune responses peak resulting in 
resolution of viremia and a partial rebound in CD4+ cells (116). The asymptomatic phase 
of the disease is referred to as clinical latency. Clinical latency lasts approximately 8 
years but can be prolonged to over 20 years with HAART, cocktails containing 
combinations antiretroviral agents (62, 122). This stage of disease is characterized by 
persistent viral replication held in tight control by the immune system (32). During 
clinical latency several hundred rounds of viral replication, immunological pressure, and 
generation of escape mutants result in an increasingly heterogeneous population of 
viruses (32, 91). Acquired immunodeficiency syndrome (AIDS) is the last stage of HIV 
pathogenesis. AIDS commences when CD4+ T helper cell counts drop below 200 
cells/mm3 of blood and viremia begins to rise. Progressive AIDS disease is associated 
with a dramatic deterioration of clinical outlook including the acquisition of opportunistic 
diseases, malignancies, and disruption of lymphoid architecture. The death of massive 
numbers of lymphoid cells results in an inability to combat opportunistic pathogens. The 
patient then succumbs to these infections resulting in death (152, 184). 
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Figure 1. Typical course of HIV infection. Time courses of CD4+ T-cell counts 
(black line), viremia (red line), and cytotoxic T-cell (CTL) counts (blue line) 
during HIV infection and disease progression. Modified from Pantaleo et al. 1993. 
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Retroviruses and HIV-1: Structure and Genetic Organization 
  All retroviral genomes are flanked by non-coding sequences called Long 
Terminal Repeats (LTR). LTR sequences contain promoter elements, packaging signals, 
and transcription enhancement elements, which are critical to the process of reverse 
transcription and are thus essential to the virus life cycle. In addition, all retroviruses 
contain four essential genes gag, pro, pol, and env (Figure 2A). These genes encode 
multiple proteins on a single polypeptide chain: Pr55Gag (Figure 2B), Pr160Gag-Pro-Pol 
(Figure 2C), and gPr160Env (Figure 2D). Individual proteins are generated from each 
polypeptide following proteolytic cleavage by the viral protease in the case of Gag and 
Gag-Pro-Pol, or by cellular furin proteases in the case of Env (72, 88, 95, 143). Simple 
retroviruses require only these four genes to replicate, while complex retroviruses like 
HIV-1 contain additional assessory genes designated tat, rev, nef, vpr, vif, and vpu. These 
contribute to defending the virus against host proteins and the host immune system 
(Figure 2A). 
 Retroviruses are spherical particles approximately 100 nm in diameter (31, 33, 
34). The surface of retroviral particles are covered with a phospholipid bilayer derived 
from the plasma membrane of the cell from which they were produced (34, 39). As a 
result, the viral membrane contains cellular membrane proteins such as cellular adhesion 
molecules (22, 112, 137). In addition, and perhaps more importantly, the viral membrane 
contains the viral attachment and entry glycosylated proteins which are encoded by the 
env gene. These env gene products are termed gp120 (SU) and gp41 (TM) for HIV 
(Figure 2D). Directly underneath the membrane, the viral Matrix (MA) protein forms a 
protein shell. Inside this MA shell resides the core, constructed from the Capsid (CA) 
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Figure 2.  HIV-1 genes, proteins, and structure. A. Diagram depicting the HIV-1 
genome and open reading frames (ORFs). Essential genes are depicted in white 
while assessory genes are in gray. B. Schematic depicting the 55 kDa Gag 
precursor gene product (Pr55 Gag). Cleavage products Matrix (p17 MA, green), 
Capsid (p24 CA, gray), Spacer Peptide 1 (p2 SP1, white), Nucleocapsid (p7 NC, 
yellow), Spacer Peptide 2 (p1 SP2, white) and p6 (p6, light blue). The N-terminal 
Interaction “I” domain is labeled in NC. C. Schematic depicting the 160 kDa Gag-
Pro-Pol precursor gene product (Pr160 Gag-Pro-Pol). Cleavage products Protease 
(p10 PR, red), Reverse Transcriptase (p66/p51 RT, dark blue), Integrase (p32 IN, 
aqua blue). D. Schematic depicting the glycosylated 160 kDa Env precursor gene 
product (gPr160 Env). Cleavage products Surface protein (gp120 SU, orange), and 
Trans-Membrane protein (gp41 TM, gold). E. Schematic depicting the mature 
HIV-1 virus particle. The location of the proteins described above are depicted. 
Also depicted are the location of the viral membrane (lipid bilayer) and RNA 
genome. 
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protein, and which contains the genomic RNA of the virus in complex with the 
Nucleocapsid (NC) protein as depicted in Figure 2E. MA, CA, and NC are gag gene 
products (Figure 2B). The viral core also contains the enzymes Reverse Transcriptase 
(RT) and Integrase (IN), which are pol gene products that aide the virus in inserting its 
genetic material into the host cell genome (35). 
 The shape or morphology of a retrovirus’ core is a distinctive feature that is 
clearly visible upon examination of a virus by electron microscopy (EM). There are four 
main types of mature virus particle morphologies, designated Type B, C, D, and 
lentivirus. Although there are four different morphologies there are only two main 
assembly patterns. Type C viruses and lentiviruses assemble and bud at the plasma 
membrane and exhibit cylindrical and conical mature core morphologies, respectively 
(Figure 4B) (34). Type B and D viruses first assemble in the cell cytoplasm as immature 
type A particles that lack a membrane. Type A particles then traffic to plasma membrane 
where they acquire a membrane during the budding process as they exit the cell and 
mature. The resulting mature core structures are spherical in shape and either 
eccentrically stuck to one side of the viral membrane (Type B particles) or centrally 
located in the virus (Type D particles). These designations are important because core 
morphology by transmission electron microscopy (TEM) has been used historically to 
classify retroviruses. 
 
HIV-1 Life Cycle and Particle Assembly 
All steps in the retroviral life cycle can be divided into two stages, early and late, as 
depicted in Figure 3 (71). The early stage spans the time between attachment of the virus 
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particle to the cell, and integration of the viral DNA into the host genome. The late stage 
begins with viral gene expression and culminates with assembly, budding, and particle 
maturation. Therefore, the viral life cycle begins with attachment of the virus to cell 
membranes. While this step has traditionally been thought to occur using the gp120 Env 
attachment protein of the virus, recent studies have provided evidence that initial contact 
between the virus and the host cell involves non-gp120-mediated interactions between 
cell adhesion molecules on both the viral and cellular membranes (92). Specifically, these 
studies show that neutralizing antibodies raised against gp120 attachment protein of the 
virus do not prevent viral attachment but instead neutralize viral infectivity by preventing 
membrane fusion. After approximately 20 minutes of attachment, the viral envelope 
protein gp120 locates and engages the viral receptor CD4 (92). 
The interaction of gp120 with CD4 initiates the early phase of the viral life cycle. 
CD4-gp120 attachment results in conformational changes that allow gp120 to bind one of 
two co-receptors, CCR5 or CXCR4 (2, 28, 46, 56, 66). After receptor attachment, the 
transmembrane protein gp41 is responsible for causing the fusion of the viral membrane 
with the cellular membrane, resulting in the viral core being released into the cell 
cytoplasm. The core then disassembles, losing the capsid shell in a process referred to as 
uncoating. The uncoating process produces a high molecular weight complex containing 
the viral genome referred to as the Pre-Integration Complex (PIC) (13, 17, 59, 63). 
During the uncoating process the virus also begins to convert its single stranded RNA 
genome into double stranded DNA in a synthesis reaction called reverse transcription. In 
this process, the viral RT enzyme first uses the RNA coding strand, or plus (+) strand, of 
the viral genome to synthesize a complementary DNA minus (-) strand, creating an 
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Figure 3.  Retroviral life cycle. Early Phase. Attachment of gp120 with the CD4 
receptor and CCR5/CXCR4 co-receptors leads to virus/cell membrane fusion. After 
entry of the core into the cytoplasm most of CA is lost during uncoating. Reverse 
transcription converts the viral RNA genome into a DNA provirus resulting in the 
creation of the Pre-Integration Complex (PIC) that enters the nucleus and integrates 
provirus into host genomic DNA. Late Phase. Viral mRNA transcribed producing 
viral proteins. Gag is made in the cytoplasm and traffics to the plasma membrane 
through a largely unknown route. Env is made in the endoplasmic reticulum (ER) 
and traffics to the plasma membrane through the secretory pathway. Particles 
assemble at the plasma membrane, bud off, and release from the cell as immature 
non-infectious particles. Proteolytic cleavage of Gag and Gag-Pro-Pol results in 
maturation and the rearrangement of the internal structure of the particle, which is 
now infectious. 
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RNA-DNA hybrid molecule. RT then degrades the RNA portion of this hybrid leaving an 
exposed single stranded DNA(-) molecule. Finally, the RT enzyme catalyzes the 
synthesis of the complemantary DNA(+) strand using the minus (-) strand as a template 
(35). It is important to note that this process creates a replication intermediate where the 
viral genome exists as a single stranded DNA molecule, thus making it susceptible to 
mutation by the viral restriction factor APOBEC3G. In the final steps of the early phase 
of virus replication, the PIC is transported into the nucleus where it integrates into the 
host genome, facilitated by the integrase (IN) enzyme. Once the virus has become part of 
the host cell genome, it is impossible to extricate and is called a provirus. The provirus 
then produces viral RNAs and proteins leading to events of the late phase of virus 
replication.  
 Late events of viral replication begin with the expression of viral RNA from the 
nucleus. The two main viral structural proteins, Gag and Env, utilize distinct mechanisms 
for expression and trafficking to the plasma membrane. These disparate mechanisms 
reflect the fact that Env is a transmembrane protein whose outer domain is on the external 
surface of the virus, while Gag is associated with the inner leaflet of the viral membrane. 
Therefore, Env is synthesized in the endoplasmic reticulum (ER) where it is inserted into 
the ER membrane with the external portions of the protein residing in the lumen of the 
ER (70). Env then traffics to the plasma membrane in vesicles of the secretory pathway 
where cellular furin proteases cleave it into the transmembrane gp41 and external gp120 
fragments during transit (95, 143). Fusion of secretory vesicles with the plasma 
membrane allows luminal protein domains, such as the gp120 portion of Env, to reside on 
the external surface of the plasma membrane, while simultaneously allowing the release 
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of luminal contents into the extracellular media (Figure 3). In contrast, Gag is synthesized 
on free cytoplasmic ribosomes from genomic full-length mRNA. Gag molecules 
multimerize, attach to the cytoplasmic face of cellular membranes, and traffic to the 
plasma membrane using cellular protein trafficking pathways (70). Gag proteins are 
cotranslationally modified by the addition of myristic acid on the amino terminal glycine 
residue, following removal of the initiator methionine (101, 171, 194). This myristate 
modification is required for plasma membrane binding of Gag and particle formation (18, 
107). Gag-Pro-Pol molecules, synthesized from the same mRNA as Gag, are the result of 
a -1 frame shift mutation which circumvents the gag stop codon and allows the ribosome 
to read through pro and pol. This event occurs when a ribosome that is near the end of the 
gag gene slips backward one base. It then begins to read the pro sequence that overlaps 
with the end of gag but exists in an alternate reading frame, producing the Gag-Pro-Pol 
fusion protein. The frame shift strategy is a way for the virus to package a reduced 
amount of Pro and Pol compared with Gag (1:20) (105), while using the same trafficking 
and targeting mechanisms to sites of assembly. 
The exact pathway that Gag follows on its way to the plasma membrane remains 
largely unknown. However, recent studies from our lab showed that Gag trafficking relies 
heavily on cellular machinery. For example, en route to the plasma membrane, Gag 
traffics through the multivesicular body (MVB) which is a late endosomal compartment 
using the cellular adaptor protein complex 3 (AP-3) (53). In addition, the NC domain of 
the Gag protein specifically binds to and recruits the genomic mRNA into virus particles, 
however, it is unclear where and when this interaction occurs and therefore what 
particular role Gag plays in genomic RNA trafficking to sites of assembly. Finally, Gag 
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and Env meet at the plasma membrane where particles are formed. Immature particles 
then require cleavage of Gag by HIV protease to become infectious. The HIV-1 life cycle 
is depicted in Figure 3. 
 
Gag Trafficking and Assembly Domains 
 During virus particle budding, Gag induces plasma membrane curvature, and 
cellular machinery is used to seal and release immature and non-infectious viral particles 
(Figure 4C) (80, 187). Immature retroviral particles contain all of the structural proteins 
of the virus in the precursor form (Pr55 Gag, Pr160 Gag-Pro-Pol) stuck to the underside 
of the viral membrane (10, 81, 85, 140). Examination of immature particles by 
Transmission Electron Microscopy (TEM) shows the electron dense protein material in 
the immature particle as a dark circle just inside the limiting membrane of the virus 
(Figure 4A) (53). During or after particle release, the HIV-1 protease cleaves Gag into 
MA, CA, spacer peptide 1 (p2), NC, spacer peptide 2 (p1), and p6 proteins. These 
products reassemble into the mature infectious particle exhibiting the distinctive 
lentivirus core structure (Figure 4B) (53, 87). 
The HIV-1 Gag protein is responsible for directing the production and assembly 
of retroviral particles (71). Therefore, the expression of Gag alone in cell culture is 
sufficient to produce non-infectious virus-like particles of normal density (84). This 
process is depicted in figure 4D and is identical to HIV-1 budding, except this occurs in 
the absence of other HIV-1 gene products or RNA. To accomplish this, Gag molecules 
contain distinct functional domains that carry out essential tasks in the HIV-1 assembly 
process. These include the M domain in MA, the N-terminal and C-terminal CA domains, 
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Figure 4.  Stages in particle budding. A. Electron micrographs of HIV-1 budding 
and immature viral particles. B. Electron micrographs of mature HIV-1 viral 
particles. A-B adapted from Dong et al. 2006. C. Schematic diagram of HIV-1 
budding and maturation. D. Schematic diagram of Gag virus-like particle budding.  
 
 19 
the I domain in NC, and the L domain in p6. The M domain causes the localization of 
Gag to the plasma membrane through the insertion of myristic acid into the lipid by-layer 
and the interaction of basic matrix residues with the negatively charged membrane (206). 
Both interactions are necessary for efficient plasma membrane localization of Gag (179). 
The C-terminal domain (CTD) of CA contains sequences necessary for CA dimerization, 
Gag-Gag interactions, and particle assembly (168, 189). The CTD also contains a 20 
amino acid region called the major homology region (MHR) that is highly conserved 
among retroviruses, however, the function of the MHR remains largely unknown (195). 
The I domain region within NC promotes Gag-Gag interaction (19). This region is also 
critical for Gag-membrane binding and proper retroviral particle density (164, 165). The 
assembly functions of the I domain are widely thought to work via the RNA binding 
properties of basic residues located in the N-terminal region of NC. The L domain is 
responsible for enabling the final separation of the budding viral particle from the cell by 
recruiting the Tsg101 protein which is a member of the vacuolar protein sorting pathway 
(80). Tsg101 recruits associated Endosomal Sorting Complexes Required for Transport 
(ESCRT) to sites of budding by binding to the PTAP motif located in the p6 region of 
Gag (187).  
 
Viral RNA Trafficking 
Retroviral mRNA synthesis requires host cell transcription machinery and 
transcription factors that bind promoter elements within the 5’ LTR. The host RNA 
polymerase II complex and associated complexes perform basal transcription of HIV-1 
RNA by binding to the TATA box region upstream of the Gag ATG start site. The 
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cellular transcription factors NF-κB and Sp-1 are the major promoters of viral RNA 
synthesis (155). NF-κB is significant because it is used by host immune cells during 
activation, thereby stimulating HIV-1 replication during immune cell activation. Host cell 
splicing of HIV-1 mRNA produces the early gene products tat, rev, and nef. The HIV-1 
Tat protein binds to a stem loop structure known as TAR located with the first 59 RNA 
bases synthesized by the RNA polymerase II (99, 144, 163). This binding event promotes 
the elongation of HIV-1 RNA by hundreds to thousands of fold, thereby increasing early 
gene protein expression (44, 68). Once sufficient Rev protein accumulates, it is 
transported back into the nucleus and binds to a highly structured group of RNA stem-
loops within the env gene referred to as the Rev Response Element (RRE) (115, 129, 
201). The nuclear export factor Crm1 then binds to the Rev Nuclear Export Signal (NES) 
(9), causing the export of singly spliced and unspliced genomic mRNA, and increasing 
the expression of the HIV-1 late genes  vpu, env, vpr, vif, gag, pol (198). Viral genomic 
RNA is recruited into virus particles through a specific interaction between the NC region 
of the Gag protein and the Psi (ψ) packaging signal, an RNA stem-loop structure located 
immediately upstream of the Gag ATG start site. However, little is known about how 
Gag locates the genomic RNA in the cell, and the site in the cell where this interaction 
takes places. The focus of Chapter V is the development of a robust method of labeling 
HIV-1 genomic RNA with fluorescent markers that will allow us to track its trafficking in 
live cells. The co-expression of fluorescent Gag molecules will then allow us to answer 
these important questions. 
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Cytidine Deaminases and APOBEC3G 
APOBEC3G (A3G) belongs to the larger super-family of proteins called cytidine 
deaminases. This group of proteins contains several other well known proteins, including 
1) E. Coli Cytidine Deaminase (ECCDA), the prototypic cytidine deaminase whose 
crystal structure is still used to predict the present structures of mammalian cytidine 
deaminases (8, 147), 2) human apolipoprotein B mRNA editing cytidine deaminase 
subunit 1 (APOBEC1), which deaminates ApoB mRNA to create a stop codon and thus 
regulates the differential expression of ApoB-100 to ApoB-48 (73, 120), and 3) 
activation-induced cytidine deaminase (AID) which produces somatic hypermutations in 
B lymphocytes by mutating the DNA that codes for B cell receptor proteins (145). Each 
of these enzymes replace the primary amine group of cytosine with a double-bonded 
oxygen, thus converting cytidine to uridine (89). Structurally, cytidine deaminases 
contain zinc finger domains that bind to DNA or RNA (26, 94). Based upon several 
crystal structures, coimmunoprecipitation assays, and yeast two-hybrid experiments, 
these cytidine deaminases have been shown to dimerize around nucleic acids in a head-
to-tail fashion with their active sites opposing one another (147). It is therefore not 
surprising to find that A3G also forms dimeric or multimeric complexes in the presence 
of RNA (110, 193).  
The cytidine deaminase A3G inhibits the replication of retroviruses including 
HIV, simian immunodeficiency virus (SIVmac), murine leukemia virus (MLV), (98, 131, 
176, 199), retrotransposons (180) and other viruses which undergo a reverse transcription 
step such as Hepatitis B Virus (HBV) (185). Insights into the mechanisms allowing A3G 
to accomplish this task can be gained by first considering some of its biochemical and 
 22 
localization properties. A3G is expressed in peripheral blood leukocytes, spleen, testes 
and to a lower extent in the ovaries (110). It is a cytoplasmic protein that only 
hypermutates the single stranded DNA (ssDNA) of viruses that contain a cytoplasmic 
ssDNA intermediate (106). Therefore, cellular DNA is protected from attack by A3G, as 
it is double stranded and contained within the nucleus. However, retrovirus ssDNA is 
very susceptible to hypermutation provided A3G can obtain access to it during reverse 
transcription. This can happen if A3G, which can bind to both ssRNA and ssDNA (106), 
is packaged into virus particles in complex with the genomic RNA. A3G would then be 
in a position to attack ssDNA intermediates during the process of reverse transcription. 
A3G becomes incorporated into retroviral particles as they exit an infected cell. 
Upon infection of a target cell by these particles and the initiation of reverse 
transcription, the incorporated A3G causes extensive deamination of cytidines on the 
exposed cDNA minus strand created during the reverse transcription process. This results 
in extensive and lethal G to A nucleotide substitutions in the proviral DNA (98, 121, 131, 
204). For reasons not completely understood, APOBEC3G expressed in the cytoplasm of 
HIV target cells is unable to gain access to reverse transcription ssDNA intermediates. 
Thus, a critical aspect of the antiviral function of APOBEC3G is its ability to be 
packaged into assembling virions (113, 133, 177). As a result, the major focus of 
experiments in this thesis involves determining the precise mechanism by which 
APOBEC3G is packaged into virus particles. When I initiated these studies, it was known 
that APOBEC3G is packaged into particles in a NC dependent manner (124, 202). 
However, it was unclear whether RNA molecules were critical for APOBEC3G 
packaging. The experiments in Chapter II were designed to address this question. 
 23 
The Viral Infectivity Factor and APOBEC3G 
HIV-1 expresses a 23 kDa basic protein late in the replication cycle called Viral 
Infectivity Factor or Vif (78, 79, 173). Vif neutralizes A3G through a mechanism that 
ultimately leads to the exclusion of A3G from viral particles (113). Vif binds to both 
A3G and members of the cullin-ubiquitin ligase complex. These members, including 
Cullin5, Elongin B, Elongin C, and the RING protein Rbx, induce polyubiquitination of 
A3G leading to its degradation by the ubiquitin proteasome pathway (36, 65, 200). 
Elimination of cellular A3G by this mechanism prevents virion incorporation and thereby 
eliminates the antiviral activity of A3G. As a result, Vif is critical for producing 
infectious virus particles in APOBEC3G expressing cells referred to as non-permissive; 
these include primary cells and certain cell lines such as the H9 and CEM T cells (11, 37, 
61, 74, 75, 178, 188). In contrast, permissive cell lines such as HeLa, HEK 293T, Jurkat 
T cells, and SupT1 T cells do not express A3G, therefore, HIV produced in these cells is 
infectious regardless of Vif expression (176).  
 
Research Objectives 
 A3G is an RNA binding protein that is packaged into virus particles through its 
interaction with the NC region of Gag. Therefore, Gag-associated RNA may play a 
central role in facilitating APOBEC3G packaging into virus particles. This suggests that 
genomic RNA trafficking may play an important role in the assembly of retroviral 
particles. The overall goal of my research was to understand the molecular events 
surrounding APOBEC3G and retroviral RNA trafficking to the plasma membrane and 
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packaging into virus particles. To achieve this broad goal, experiments were performed 
according to the following four Specific Aims: 
 
Specific Aim 1. To define the requirements for APOBEC3G packaging into virions. 
The I domain of Gag is an N-terminal region of the nucleocapsid, which is known 
to bind RNA, and is also known to contribute assembly functions to the Gag protein. Due 
to the fact that both A3G and NC are RNA binding proteins, I hypothesized that RNA is 
required for A3G interactions with the I domain of Gag. To this end, I tested a series of 
mutant Gag constructs spanning the I domain to determine if quantitative I domain 
function correlates with A3G packaging in Gag virus-like particles (VLPs).  I also used 
membrane flotation studies to determine if I domain function correlated with the 
association of A3G to cellular membranes. Finally, I assessed RNA involvement by using 
Gag-GST pull down studies, and by comparing RNA and A3G levels in VLPs.  The 
studies in specific Aim 1 contribute important information to the role of RNA in both I 
domain function and A3G packaging. 
 
Specific Aim 2. To determine if RNA dependent A3G multimers are packaged into 
virus particles. 
 The hypothesis tested in Aim 2 was that A3G exists in RNA containing 
complexes, and that Gag recruits these complexes into VLPs through RNA binding. 
FRET fluorometry has been used previously to detect Gag-Gag interactions. Therefore, in 
order to assess the first part of this hypothesis, I used this technique to determine if A3G 
complexes are RNAse sensitive which would prove that RNA is an integral component of 
these complexes. To address the second part of the hypothesis, determining if VLP 
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associated A3G is packaged as a monomer or a complex, FRET studies were used to 
assess whether A3G complexes are a component of VLPs. In addition, I subsequently 
examined if A3G complexes are packaged through Gag binding directly to the A3G or by 
Gag binding to the RNA in these complexes. To this end, I used FRET to analyze 
whether a direct Gag-A3G interaction could be detected in VLPs. These studies provide a 
mechanistic insight into the structural relationship between Gag, A3G, and RNA 
molecules involved in virus particle assembly. It was discovered that A3G was packaged 
into virus particles as homo-multimeric complexes known to contain RNA without a 
direct interaction between A3G and Gag.  
 
Specific Aim 3. To define the subcellular localization of A3G-RNA complexes. 
 Virus particle assembly occurs at the plasma membrane. Therefore, A3G 
molecules should traffic through this location in order to be packaged into VLPs. 
Fluorescent microscopic analysis using deconvolution techniques were used to evaluate 
the localization of A3G to the plasma membrane during particle assembly. The location 
of A3G interaction in cells was determined by confocal spectral analysis of A3G FRET 
using the acceptor photobleach method. While this assay was sufficient to assess A3G 
interactions in discrete cellular locations, a novel live cell FRET microscopy technique 
was developed to determine the overall subcellular localization of A3G complexes during 
particle assembly. These studies support the model developed in previous specific aims 
by showing the recruitment of A3G multimeric complexes to the plasma membrane by 
Gag for ultimate packaging into particles through a Gag-RNA interaction.  
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Specific Aim 4. Development of a system to track retroviral genomic RNA during  
trafficking and assembly. 
The trafficking of HIV-1 genomic RNA from the nucleus to the plasma 
membrane, where assembly occurs, is critical to the formation of infectious virus 
particles. The fourth specific aim involves the development of reagents necessary to 
observe this movement. Strategies included the creation of MS2-fluorescent proteins for 
RNA labeling, and the generation of reporter RNA by the engineering of MS2 binding 
sites into proviral expression constructs and over-expression constructs. I used 
fluorescent microscopy to determine that the reporter RNAs, containing MS2 binding 
sites, caused export of the MS2-fluorescent tags into the cytoplasm. The results presented 
in this Specific Aim form the foundation for future studies on retroviral RNA trafficking. 
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CHAPTER II 
 
IMPORTANCE OF THE NUCLEOCAPSID BASIC LINKER FOR PACKAGING 
OF APOBEC3G INTO HIV-1 GAG VIRUS-LIKE PARTICLES 
 
Introduction 
 The HIV-1 Gag protein is responsible for facilitating APOBEC3G incorporation 
into virions as evidenced by the fact that Gag virus-like particles (VLPs) efficiently 
incorporate APOBEC3G (55, 182, 202). In addition, in vitro binding experiments have 
shown that APOBEC3G binds efficiently to the nucleocapsid (NC) region of the Gag 
polyprotein (1, 24, 124, 169, 182, 202). Finally, Gag constructs in which a leucine zipper 
protein-protein interaction domain replaced the nucleocapsid region produced particles 
devoid of APOBEC3G (124, 202). When my studies were launched, the precise 
mechanism by which NC recruits APOBEC3G was unclear. In particular, the role played 
by RNA and distinct RNA binding regions within NC was controversial. In vitro binding 
experiments between NC and APOBEC3G that utilize RNA depletion by RNAse A 
treatment have been reported which support (124, 169, 182, 202) or refute (1, 24) the role 
that an RNA bridge may play in this interaction. 
 An essential retroviral assembly function is contained within the N-terminal 
region of nucleocapsid (6, 14, 191). This region, termed the interaction domain (“I” 
domain), is necessary for Gag-Gag multimerization, the formation of detergent-resistant 
Gag complexes, plasma membrane localization of Gag, and the formation of normal 
density retroviral particles (47, 164, 165). The I domain has been implicated in mediating 
RNA binding to NC through electrostatic interactions of basic residues with cellular or 
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viral RNA. Furthermore, in experiments using C-terminal NC truncations of Gag, the I 
domain phenotype correlated with the number of basic residues expressed (164). 
Therefore, it seemed reasonable to hypothesize that APOBEC3G incorporation might be 
linked to the assembly functions associated with the I domain. 
In the studies described in this Chapter, I examined the requirements for 
APOBEC3G incorporation into HIV virus-like particles (VLPs). Surprisingly, I found 
that APOBEC3G incorporation did not correlate closely with the presence of the I 
domain. Rather, mapping of APOBEC3G incorporation and RNA revealed a key role for 
the basic linker region of Gag, located between the two zinc finger domains of NC. The 
amount of RNA incorporated into particles did correlate, however, with APOBEC3G 
recruitment to the plasma membrane and packaging into particles. Thus, taken together 
we conclude that the basic linker region in NC is essential for RNA-dependent 
APOBEC3G recruitment into virus particles. 
 
Materials and Methods 
 
Plasmid construction 
This study employed Gag and APOBEC3G expression constructs fused to 
variants of the codon-optimized version of CFP and YFP (Clonetech, Palo Alto, CA). 
Some of the CFP and YFP expression vectors, and several of the Gag expression 
constructs were previously described (47). Briefly, the C-terminal CFP and YFP 
expression constructs were created by first replacing the EGFP gene in pEGFP-N3 
(Clontech) with either the CFP gene from pECFP-N1 or the YFP gene from pEYFP-N1. 
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These new constructs were designated pECFP-N3 and pEYFP-N3, respectively (47). The 
N-terminal YFP expression construct was produced by replacing the EGFP gene in 
pEGFP-C1 (Clontech) with the YFP gene from pEYFP using an AgeI site located 5’ to 
the ATG start site in both plasmids and a BsrGI site located in the 3’ end of both genes 
prior to the stop codon. This new construct was designated pEYFP-C1. The Gag coding 
sequences for all constructs were derived from the codon-optimized version of HXB2 
Gag in expression plasmid pVRC3900 (104). PCR cloning was then used to amplify the 
gag gene from the pVRC3900 vector, with a HindIII site at the 5’ ATG and a BamHI site 
at the 3’ end.  The amplified gag gene was then ligated into both pEYFP-N3 and pECFP-
N3 by digestion of the BamHI and HindIII sites located within the multiple cloning 
regions. A schematic diagram of the Gag expression constructs employed in this study is 
shown in Fig. 7B. The APOBEC3G coding sequences for all constructs were derived 
from the plasmid CEM15 that was obtained from Michael Malim along with a C-terminal 
HA-tagged version, both of which were previously described (176). These constructs are 
referred to hereafter as APOBEC3G and APOBEC3G-HA. PCR cloning was used to 
amplify the APOBEC3G gene with an EcoRI site prior to the 5’ ATG and an SmaI site at 
the 3’ end. The amplified APOBEC3G gene was then ligated into pEYFP-N3 by 
digestion of the EcoRI and SmaI sites located within the multiple cloning region. This 
new construct was designated A3G-YFP.  
 The oligonucleotides used in PCR amplifications for Gag-CFP constructs were 
GTCAAGCTTGTCGACATGG GCGCCCGCGCCAGC-(F) (forward oligonucleotide 
for all Gag-CFP constructs), CGGGATCCCTTCACGATCTT GCGCTG-(R) (Gag391-
CFP), CGGGATCCGCAGTTGCGGGCGGTGTG-(R) (Gag405-CFP), 
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CGGGATCCCTTC TTGCGGGGGGCGCG-(R) (Gag411-CFP), 
CGGGATCCGCAGTCCTTCATCTGGTG-(R) (Gag426-CFP), CGG 
GATCCATTAGCCTGTCGCTCGGTG-(R) (Gag432-CFP). Oligonucleotides used in 
PCR amplifications for A3G-YFP construct were 
GGAATTCGCCACCATGAAGCCTCACTTCAGAAAC-(F), 
TCGCCCGGGTTTTCCTGATTCTG GAG-(R). 
 
Cell lines and transfections 
The human kidney cell line 293T was maintained in Dulbecco’s modified Eagle 
medium with 10% fetal bovine serum and antibiotics at 37°C in 5% CO2, and grown in 
100-cm2 tissue culture dishes. Transfections were performed by either the calcium 
phosphate-BBS transfection method or with Lipofectamine 2000 (Invitrogen, Carlsbad, 
Calif.), with 10 µg of total plasmid DNA unless otherwise stated. 
 
Production and purification of immature Gag virus-like particles (VLPs) 
Cell culture supernatants from transfected 293T cells were harvested 48 to 72 
hours post-transfection, clarified by centrifugation, filtered through a 0.45-µm filter, and 
pelleted through a 20% sucrose cushion (100,000 × g for 2 h at 4°C). The pellets were 
resuspended in 1.0 mL of phosphate-buffered saline (PBS) and analyzed by scanning 
cuvette fluorometry using a tunable PTI cuvette fluorometer (Photon Tehnology 
International, Lawrenceville, NJ). 
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Gradient analysis of Gag VLPs 
Gag VLPs, purified as described above, were analyzed by centrifugation on linear 
20 to 60% sucrose gradients. Particles resuspended in PBS were overlaid on linear 20 to 
60% sucrose gradients.  Ultracentrifugation was performed at 100,000 × g overnight at 
4°C in a Beckman SW41 rotor. Equal fractions were collected, and the density of each 
fraction was determined with a refractometer. Samples were subsequently diluted in PBS 
and pelleted at 100,000 × g for 2 h at 4°C in a Sorvall S45A rotor. Samples were 
resuspended in 100 µl of PBS. Protein content was analyzed by scanning cuvette 
fluorometry and RNA content was analyzed by RiboGreen dye incorporation after 
treatment with RQ1 DNAse according to the manufacturer’s instructions. Briefly, 10 µl 
of each fraction was incubated with 0.1 units/µl of RQ1 DNAse and half the supplied 
reaction buffer (5 mM MgSO4, 20 mM Tris-HCl, 0.5 mM CaCl2) in PBS for 2 hours at 
37°C. Samples were then incubated with 0.1% SDS at 65°C for 20 min to lyse particles. 
An equivalent volume of RiboGreen (Invitrogen, Carlsbad, CA), diluted 200 fold in TE, 
was then added and allowed to sit in the dark for 10 min. Samples were read on a 
VersaFluor (BioRad Laboratories, Hercules, CA) cuvette fluorometer along with RNA 
standards. The original concentration of RNA was then calculated. 
 
Antibodies and Immunoblotting 
Particle and lysate preparations were analyzed by SDS-polyacrylamide gel 
electrophoresis followed by transfer to a nitrocellulose membrane and immunoblotting. 
Gag was blotted with sera pooled from HIV seropositive patients. APOBEC3G antisera 
was provided by Warner C. Greene through the NIH AIDS Research and Reference 
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Reagent Program (181). Secondary horseradish peroxidase conjugated antibodies for 
ECL-film analysis were obtained from Promega (Madison, WI). Secondary fluorescent 
conjugated antibodies for detection on the LiCor Odyssey were obtained from LI-COR, 
Inc. (Lincoln, Nebraska). 
 
Isolation of membrane fractions and analysis by scanning cuvette fluorometry 
Cells were harvested for analysis 48 hours following transfection. Three 10 cm2 
dishes of nearly confluent 293T cells were included for each experimental sample. Cells 
were washed in phosphate-buffered saline, allowed to swell in hypotonic buffer (10 mM 
Tris-Cl pH 8.0, plus protease inhibitors) for 20 min on ice, and broken by dounce 
homogenization. The lysates were then adjusted to 0.1 M NaCl, and the nuclei and 
unbroken cells were removed by centrifugation at 1000 × g for 10 min. For isolation of 
membrane fractions, postnuclear supernatants containing cytosolic and membrane 
components were then adjusted to 50% iodixanol from a stock solution of 60% iodixanol 
(Nycomed Pharma, Oslo, Norway). Forty percent and ten percent solutions of iodixanol 
were layered on top of the 50% iodixanol layer. The preparation was centrifuged in a 
Beckman SW41 rotor at 41,000 rpm for 2 h at 4°C. The membrane fraction was taken 
from the 10%-40% iodixanol interface as a 1-mL sample. Each sample was kept at 4°C 
and analyzed by fluorometry in a PTI T-format scanning cuvette spectrofluorometer 
(Photon Tehnology international, Lawrenceville, N.J.). For analysis of CFP emission to 
compare the relative amount of CFP present, samples were excited at 433 nm, and an 
emission scan was performing ranging from 460 to 550 nm. For analysis of YFP 
emission to compare the relative amount of YFP present, samples were exited at 513 nm, 
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with an emission scan ranging from 524 to 534 nm. Data were collected from at least 
three different independent experiments for each expression construct. 
 
Results 
 
Specificity of APOBEC3G packaging into Gag VLPs 
We first confirmed the findings of other groups that Gag alone is sufficient to 
package APOBEC3G into VLPs (1, 24, 55, 124, 169, 202). To this end, Gag VLPs were 
produced in 293T cells in the presence and absence of APOBEC3G-HA overexpression. 
When APOBEC3G-HA was expressed alone, it was not released into the cell culture 
media. However, Gag expression and VLP production were sufficient to release 
APOBEC3G into the cell culture media (Figure 5A). In order to facilitate quantitative 
studies of the specificity of APOBEC3G packaging into Gag VLPs, a fluorescent system 
of tracking the relative amounts of APOBEC3G and Gag was developed using an 
APOBEC3G-YFP fusion protein (hereafter referred to as A3G-YFP). Packaging of A3G-
YFP into Gag VLPs was readily demonstrated (Figure 5B), indicating that APOBEC3G-
fluorescent protein fusions may be useful in further characterizing the determinants of 
APOBEC3G packaging. 
 
APOBEC3G-YFP is functional and potently restricts the replication of HIV 
Prior to mapping the NC region critical for APOBEC3G packaging, it was 
necessary to verify that A3G-YFP behaves like untagged APOBEC3G in every way 
including its ability to dramatically reduce the infectivity of HIV particles. In addition, 
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Figure 5. APOBEC3G incorporation into Gag VLPs. (A) APOBEC3G bearing 
an HA tag was expressed in 293T cells in the presence or absence of Gag. 
Shown are immunoblots probed with anti-HA antibody (top) and pooled HIV 
patients’ sera (bottom). (B) A3G-YFP or YFP alone was co-expressed with Gag-
CFP, and the amount of YFP incorporated into Gag-CFP particles and 
corresponding cell lysates were quantified using a scanning cuvette fluorometer. 
Results are shown as a percent of total Relative Fluorescence Units (RFU) 
released (supernatant/supernatant + cell). 
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Figure 6. APOBEC3G-YFP potently restricts HIV-1 strain NL4-3. NL4-3 virus 
was produced from 293T cells co-transfected with 10 µg of the indicated provirus 
and 1.5 µg of either pcDNA3.1, APOBEC3G (A3G), or APOBEC3G-YFP (A3G-
YFP). Infectivity of each virus (TCID50/ml) was assayed using a luciferase 
reporter gene in the TZMBL cell line. The infectivity is reported as normalized to 
virus concentration in nanograms of CA p24 per ml. Expression of either A3G or 
A3G-YFP was sufficient to reduce the infectivity of HIV-1 virus by 100 fold. 
However, an otherwise identical provirus lacking Vif expression produced virus 
that was reduced in infectivity by 100, 000 fold in the presence of both A3G and 
A3G-YFP expression. 
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the use of APO-YFP on a provirus lacking Vif such as NL4-3∆Vif should produce a 
more profound effect on the infectivity of the released particles due to the absence of Vif-
induced A3G degradation. Therefore, NL4-3 and NL4-3∆Vif viruses were produced in 
the presence of pcDNA3.1 vector only, A3G, or A3G-YFP. The concentration of each 
virus was first determined by p24 ELISA. The infectivity of each virus was then 
determined using the Tissue Culture Infective Dose (TCID50/ml) method and infection 
of the HIV reporter cell line TZMBL. The results are illustrated in Figure 6 as infectivity 
normalized to virus content (TCID50/ng p24). Both A3G and A3G-YFP were able to 
reduce the infectivity of NL4-3 by 100 fold and of NL4-3∆Vif by 100, 000 fold. This 
indicates that A3G-YFP is just as potent as A3G in restricting virus infectivity and 
therefore virus replication. In addition, based on the more profound restriction effects of 
A3G-YFP on NL4-3∆Vif, I concluded that A3G-YFP is as susceptible to Vif degradation 
and neutralization as A3G. Together, these data confirmed that A3G-YFP is an 
appropriate and relevant tool to study A3G packaging into HIV particles. Most 
interestingly, however, was the observation that even wild type HIV-1 can be restricted 
quite effectively by the correct expression levels of A3G. This suggests that the studies 
presented in this thesis can be applied to clinical strains of HIV-1 in the unusual context 
of APOBEC3G over-expression. 
 
Efficient APOBEC3G incorporation requires the NC basic linker region 
The packaging of APOBEC3G into virions or VLPs has been shown by a number 
of groups to be dependent on the NC region of Gag (1, 24, 124, 169, 182, 202). We 
sought to more precisely delineate the region of NC required for APOBEC3G packaging, 
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and to determine if APOBEC3G packaging sequences directly correlate with the “I” or 
Interaction domain which localizes to NC (47, 164, 165). To this end, we utilized a panel 
of Gag protein constructs spanning the NC region fused to CFP (Fig. 7B). These 
constructs have been extensively characterized for their ability to produce particles of 
normal density, their membrane-binding properties, and their ability to interact with 
detergent-resistant membrane fractions (51, 164, 165). I reasoned therefore that these 
properties might be correlated with APOBEC3G packaging. 
To test this, VLPs were collected and purified from 293T cells that were cotransfected 
with A3G-YFP and each of the Gag-CFP fusion constructs. Relative levels of Gag were 
determined by CFP fluorescence, and relative APOBEC3G levels were determined by 
YFP fluorescence. Approximately equivalent expression levels of APOBEC3G in each of 
the cell lysates examined was verified by YFP fluorescence (data not shown). Very small 
amounts of APOBEC3G were released in the absence of Gag (Fig. 5B), presumably in 
microvesicles that co-purify with the VLPs. The small amount of A3G-YFP released in 
the absence of Gag (always less than 5% of values in the presence of Gag) was subtracted 
from the fluorescence values in the presence of each of the Gag-CFP constructs, and the 
Gag-dependent packaging of A3G-YFP plotted (Fig. 7C). Values are expressed as YFP 
relative fluorescence units (counts/sec), divided by CFP relative fluorescence units 
(counts/sec).  
 Gag377-CFP expresses MA, CA, and SP1 of Gag, and the particles produced 
from this protein failed to package APOBEC3G (Fig. 7C). Gag384-CFP includes the 
minimal “I” domain(164), yet unexpectedly also failed to package APOBEC3G. 
Additional constructs that did not contain the basic linker region (between amino acids 
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Figure 7. Nucleocapsid determinants of APOBEC3G incorporation. (A) Schematic 
illustration of Pr55Gag and position of the N-terminal I Domain and selected amino 
acids. (B) Schematic representation of Gag-CFP constructs subdividing HIV-1 NC. 
Asterisks indicate the sites of Gag truncation and CFP fusion.  The number 
represents the C-terminal amino acid residue expressed, with the Gag initiator 
methionine considered residue 1.  Arrows represent HIV protease cleavage sites. 
(C) Gag-CFP fusion constructs illustrated above were cotransfected with A3G-YFP. 
Supernatants were concentrated through 20% sucrose cushion. A3G-YFP released 
in microvescicle contamination is estimated by the YFP fluorescence released when 
A3G-YFP is co-transfected with pcDNA control and represented less than 5% of the 
signal seen upon expression of full-length Gag. This value is subtracted and the 
resulting Gag-induced Relative Fluorescence Units (RFU) of A3G-YFP released is 
shown as a normalized value relative to the amount of Gag protein present. (D) 
Gag-CFP fusion constructs illustrated above were cotransfected with APOBEC3G. 
Supernatants were concentrated through 20% sucrose cushion. CFP fluorescence 
was used to normalize virus like particle concentration. Proteins were resolved by 
SDS-polyacrylamide gel electrophoresis followed by immunoblot analysis with 
APOBEC3G anti-sera and pooled HIV patient sera for Gag-CFP.  
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405 and 411) were released into the media in the form of VLPs, but packaged very little 
APOBEC3G. This was also true for Gag405-CFP, a Gag-CFP fusion construct that 
includes the intact N-terminal zinc finger domain, which failed to package APOBEC3G 
above background levels (Fig. 7C). However, the addition of the six amino acid basic 
linker region represented in Gag411-CFP produced a sharp increase in packaging 
efficiency. Interestingly, constructs that contain the basic linker plus the second zinc 
finger region but lacking p6 incorporated an enhanced amount of APOBEC3G compared 
to wild type Gag using this assay. 
 To ensure that this packaging phenotype was not an artifact of the YFP fusion 
construct, these experiments were repeated with an untagged APOBEC3G construct. In 
this experiment, the VLP pellets were normalized for loading by measuring the amount of 
Gag as indicated by CFP fluorescence, and the incorporated APOBEC3G protein was 
detected by Western blotting on a LiCor fluorescence imaging system.  Gag411-CFP, a 
construct containing the basic linker, demonstrated APOBEC3G packaging, as did 
constructs including the second zinc finger and the entire NC region (Figure 7D). 
Together, these results confirmed the dependence of APOBEC3G packaging on the 
nucleocapsid region, and suggested that the basic linker is required for incorporation. 
Strikingly, the packaging requirements of APOBEC3G were distinct from the minimal 
“I” domain, which has been mapped more proximally to the N-terminal domain of NC 
(164). 
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RNA content of particles correlates with APOBEC3G content 
Both APOBEC3G and the nucleocapsid (NC) subunit of Gag are known to bind 
ribonucleic acids (RNA), however, the role of RNA binding in packaging has not been 
completely resolved. While some investigators report RNA-dependent packaging (169, 
182, 202), others have reported a direct APOBEC3G-NC interaction (1, 24).  If the ability 
of NC to bind to cellular RNA is the prime determinant of APOBEC3G packaging into 
HIV VLPs, then we would expect that the amount of RNA packaged in VLPs should 
correlate with the quantity of APOBEC3G packaged. Furthermore, truncated Gag 
constructs that lack subdomains of NC may package less cellular RNA. In order to test 
these hypotheses, VLPs from several of the constructs outlined in Fig. 7B were purified 
by equilibrium density sedimentation on a linear sucrose gradient. Equal fractions were 
collected, treated with DNAse, and analyzed for protein content by CFP fluorescence, 
and for RNA content by incorporation of the fluorescent dye RiboGreen (Molecular 
Probes). The RNA content of each construct expressed as an RNA/Gag fluorescence ratio 
present in the 1.16 g/ml particle peak is shown in Fig. 8A, and a representative curve 
demonstrating co-fractionation of total RNA and Gag is shown in Fig. 8B. We found 
measurable RNA incorporation in constructs representing the “minimal” I domain 
(Gag384, Fig. 8A), which did not increase substantially when the entire N-terminal 
domain was included (Gag405). Inclusion of the NC basic linker substantially increased 
the RNA/Gag ratio (Gag411), and inclusion of full-length NC enhanced this further 
(Gag432). The pattern of RNA incorporation that we observed closely mimicked the 
relative levels of incorporation of A3G-YFP (compare Fig. 8A and Fig. 7C). These data 
support a model in which APOBEC3G binds to the cellular RNA that is incorporated into 
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Figure 8. RNA content of particles correlates closely with APOBEC3G content. 
Gag-CFP fusion constructs were transfected into 293T cells. Supernatants were 
purified on linear 20 to 60% sucrose gradients. Fractions were collected from the top 
of the gradient, treated with RQ1 DNAse, stained with RiboGreen, and subjected to 
analysis by fluorometry. (A) RNA content of particles in peak fractions are shown 
normalized to Gag-CFP content (RNA/Gag ratio). (B) Sedimentation pattern of Gag-
CFP VLPs (black squares) and associated RNA (gray circles). 
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the developing virion, and indicates that the quantity of APOBEC3G incorporated is 
greatest in those particles with the highest RNA content, which in this experiment was 
the result of non-specific interactions between NC and cellular RNA. Interestingly, the 
very low level of APOBEC3G packaged in the absence of the basic linker region (Fig. 
7C), despite packaging of some cellular RNA by Gag384 and Gag405, argues that there 
may be either a specific contribution of the basic linker region of NC for packaging or a 
threshold level of RNA incorporation that dictates packaging. 
 
NC basic linker is required for membrane recruitment of APOBEC3G 
Particle budding is known to occur at the plasma membrane in both primary T 
cells and 293T cells (71). Therefore, we examined whether Gag constructs that packaged 
APOBEC3G also recruited it to membrane fractions. To this end, 293T cells were 
cotransfected with A3G-YFP and the panel of Gag-CFP truncation mutants, and 
membranes were isolated via flotation on iodixanol gradients. The membrane-enriched 
fraction was collected and assayed along with the cell lysates for APOBEC3G and Gag 
protein content by YFP and CFP fluorescence, respectively. Results are expressed as 
percent membrane fluorescence compared to total cell lysate fluorescence (Fig. 9). 
Marked recruitment of APOBEC3G to cellular membranes was observed upon 
expression of Gag (Fig. 9A). The recruitment of APOBEC3G to the membrane fraction 
largely mirrored the results described above for particle incorporation; those constructs 
lacking the basic linker failed to recruit APOBEC3G into membrane fractions. In parallel, 
we measured the membrane flotation of Gag (Fig. 9B). Remarkably, Gag membrane  
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Figure 9. Nucleocapsid determinants of APOBEC3G membrane recruitment. 
Gag-CFP fusion constructs illustrated in Fig. 2B were cotransfected with A3G-
YFP. The protein content of membrane-enriched fractions generated by flotation 
on iodixanol step gradients was determined by fluorescence spectrophotometry.  
The percentage of protein present in the membrane fraction was calculated by 
dividing by the protein present in the total cell lysate. (A) YFP signal was used to 
determine the amount of APOBEC3G present in membrane fractions for each 
indicated construct. (B) CFP signal was used to determine the amount of Gag 
protein present in membrane fractions for each indicated construct. 
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association was maximal with the inclusion of the N-terminal domain of NC. Addition of 
the basic linker did not enhance Gag-membrane association in this context (Fig. 9B). The 
association of Gag constructs bearing only the N-terminal subdomain of NC with 
membranes is consistent with our previous description of the I domain (164), and 
indicates that the determinants mapped as the I domain are distinct from the packaging 
requirements for APOBEC3G. These data support a more specific role for the basic 
linker region in APOBEC3G interaction and recruitment to cellular membranes. 
 
RNAse disrupts APOBEC3G binding to NC 
Indirect evidence has indicated the importance of RNA in the recruitment of 
APOBEC3G into Gag VLPs. To directly assess the question of RNA involvement a GST 
sedimentation assay was employed. Cell lysates expressing APOBEC3G-HA were added 
to each Gag subunit, fused to GST, and conjugated to glutathione sepharose beads. After 
extensive washing, it was found that APOBEC3G-HA bound only to the NC region, and 
not to other Gag subunits (Fig. 10A). When cell lysates were treated with nucleases, this 
binding was abolished (Fig. 10B). These results are consistent with those already 
published by several groups, further supporting an important role for RNA in particle 
incorporation of APOBEC3G (169, 182, 202). 
 
Discussion 
APOBEC3G (A3G) is a very potent inhibitor of viral replication and therefore a 
complete understanding of its function is vital. A3G packaging into viral particles 
represents an essential step in A3G function and therefore the viral protein sequences  
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Figure 10. RNAse disrupts APOBEC3G binding to NC. (A) Cell lysates from 
293T cells expressing APOBEC3G-HA were added to glutathione agarose beads 
containing the indicated bacterially purified Gag subunits.  After extensive 
washing the glutathione beads were analyzed by SDS-PAGE followed by both 
coomassie blue staining and immunoblot analysis with αHA for APOBEC3G-HA. 
In = 5% of input (B) As described above following addition of RNAse and DNAse 
to the cell lysates prior to performing GST pulldown. 
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facilitating this process are of great interest within the field of A3G and the wider field of 
HIV research in general. The studies presented in this chapter provide three unique 
contributions to the field of A3G research. First, I have developed a novel method to 
quantitatively characterize the levels of A3G in the cytoplasm, on cellular membranes, 
and in particles using fluorescence spectroscopy. Secondly, I have mapped the Gag 
determinants of A3G packaging to a specific region of NC. Finally, I have demonstrated 
the requirement for RNA in A3G packaging using both correlative cell culture techniques 
and direct biochemical methods. These contributions advance the field in two main ways, 
by providing a new method that can be used to quantitatively study the steps in viral 
encapsidation of any fluorescent fusion protein, and in addition, my contributions have 
provided the field with new insights regarding the specific mechanisms driving A3G 
packaging into virus particles. 
Previously, two methods were used to detect A3G content in particles involving 
either immunoblotting or a radiolabelled cytidine deamination assay (176, 181, 182). 
However, immunoblotting is only semi-quantitative and both procedures involve several 
hours of biochemistry before A3G concentration can actually be determined. Fluorescent 
analysis of GFP variant fusion-proteins within whole particles provides a linear and 
quantitative signal that can be obtained within minutes. Therefore, YFP fluorescence was 
used measures A3G-YFP levels, and CFP fluorescence was used to normalize A3G levels 
to the amount of Gag-CFP present. This assay provides a sensitive and reliable way to 
detect A3G that is also very quick to perform and easy to learn.  This convenient assay 
can be adapted to measure viral incorporation of any fluorescent fusion protein, and can 
also be generalized to other viruses provided they have a structural protein that can 
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support GFP fusion. As a result this technique is of general utility and interest to the HIV 
field.  
 A number of published reports have established that the NC region of Gag is 
necessary for APOBEC3G packaging into virions or VLPs. The N-terminal subdomain of 
NC has been shown to be sufficient to allow the formation of particles of normal 
retroviral density. The “I” domain, which is located within this region, is widely believed 
to contribute to Gag-Gag multimerization, mediated by NC-RNA interactions. I was 
surprised in this study to find that the minimal “I” domain of Gag, an essential assembly 
determinant, did not correspond precisely with the packaging requirements for 
APOBEC3G. Rather, only those constructs that included the first zinc finger and basic 
linker packaged APOBEC3G. In contrast to my study is that of Luo et al. (124), who 
showed that one Gag protein truncated proximal to the first zinc finger packaged 
APOBEC3G. While the reason for this discrepancy is not certain, I propose that it reflects 
the fluorescent quantitation performed in my study versus the semi-quantitative Western 
blot analysis performed in the Luo et al. study. In agreement with their results, however, I 
observed a minor amount of APOBEC3G in all truncated constructs (Fig. 7D). Two 
additional lines of experimentation were used to verify the importance of the basic linker 
region of NC for A3G packaging into particles. First, these studies were repeated, with 
identical results, using untagged A3G and a quantitative western blotting technique (Fig. 
7D). Second, using the same panel of C-terminal Gag truncation mutants and a 
membrane flotation assay, I demonstrated that the basic linker region of NC was also 
necessary for Gag to recruit A3G molecules to cellular membranes (Fig. 9A). This 
finding was particularly interesting because a logical timeline of assembly events would 
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suggest the necessity of localizing A3G to the plasma membrane prior to its incorporation 
into virus particles. Nevertheless, two possible explanations for how this might occur 
exist: 1) that Gag recruits A3G that is already on the plasma membrane into particles, or 
2) that Gag recruits A3G from other cellular locations to the plasma membrane and then 
into particles. The membrane flotation evidence suggests the latter as the mechanistic 
explanation for A3G plasma membrane recruitment, but also confirms the importance of 
the basic linker region of NC for this process. Therefore, the quantitative packaging data, 
and the data indicating that membrane recruitment requires the same critical region, 
emphasizes the importance of the basic linker region of NC for APOBEC3G interaction 
and packaging. Furthermore, these studies provide the field with a deeper mechanistic 
understanding of how cellular A3G molecules make their way into virus particles. 
The nature of RNA involvement in A3G packaging has been a controversial issue 
in the literature. The majority of reports support an essential role for RNA in mediating 
the APOBEC-NC interaction (169, 182, 202), although some investigators have found 
evidence for a direct protein-protein interaction (1, 24). Our findings support an RNA-
dependent incorporation of APOBEC3G into particles using several lines of evidence. 
First, in vitro interactions of APOBEC3G and NC were shown to be RNAse sensitive as 
reported by others. Secondly, we found that the incorporation of APOBEC3G into 
particles generated from a series of truncated Gag protein constructs correlated well with 
the RNA-to-Gag ratio of the released particles. Essentially, particles generated from Gag 
constructs containing the basic linker region of NC that packaged wild-type levels of 
A3G also contained wild-type levels of RNA. The Gag426-CFP and Gag432-CFP 
constructs contain the basic linker region, additional C-terminal NC sequence with added 
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basic residues, but none of the p6 region. Particles produced from expression of these two 
constructs contained higher than wild type levels of A3G but also higher than wild type 
levels of RNA, supporting the hypothesis that A3G packaging depends upon RNA 
packaging. The exact explanation for why the particles generated from these two 
constructs contain higher than wild-type levels of both A3G and RNA remains unclear. 
Nevertheless, several possible hypothesis will be explored during my discussion of a 
model below. These studies are a significant contribution to the field because they help to 
resolve the conflict over the requirement for RNA in A3G packaging from the 
unexplored angle of using cell culture experiments in combination with biochemistry to 
make this point.  
 The studies presented in this chapter provide information that allows me to 
develop a mechanistic model of how A3G is recruited into virus particles. It is known 
that A3G molecules bind to single stranded RNA molecules within the cytoplasm that 
contain uridine and are longer than 16 base pairs in length (106). Therefore, during viral 
infection A3G molecules bind to viral genomic RNA as it traffics to the plasma 
membrane and into virus particles. This packaging of RNA is facilitated by the viral Gag 
protein which recruits viral RNA specifically, and cellular mRNA non-specifically, into 
virus particles through interactions with the NC region. Therefore, Gag is involved in 
causing viral packaging of A3G through its ability to package RNA into particles. It is of 
note to remark that whether the RNA binds first to A3G or Gag may have different 
implications. This model predicts that any virus whose RNA genome traffics through the 
cytoplasm of a cell expressing A3G would package A3G into viral particles unless 
specific mechanisms were employed by the virus to exclude A3G from particles. Of 
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course, other RNA viruses, that do not have a ssDNA replication intermediate, may 
package A3G but experience no resulting decrease in infectivity. Reports show that 
several other retroviruses, endogenous retroviruses, and the Hepatitis B Virus package 
A3G molecules (52, 60, 98, 126, 131, 167).  
Several mechanisms are employed by HIV-1 to exclude A3G from virus particles. 
The first and most important method used by HIV-1 to exclude A3G from virus particles 
is by expression of the Vif protein which causes A3G degradation, reduction of its 
packaging into virus particles, and restoration of HIV-1 particle infectivity (176, 177) 
(Fig. 6). Secondly, one report has suggested that A3G may be removed from the 
cytoplasm by the production of non-infectious VLPs containing A3G (1). While the data 
presented in this chapter seems support this conclusion (Fig. 5A, 7D), the importance of 
this phenomenon during physiological virus replication is unknown. Thirdly, viral RNA 
can theoretically be protected from A3G binding through the action of a protein 
chaperone that forms a tight complex with the viral genomic RNA. This may be the 
reason why incoming HIV-1 RNA, tightly wrapped around NC subunits and further 
protected by a capsid shell, are not susceptible to mutation by A3G found in the target 
cell cytoplasm (76, 131). Lastly, structural studies suggest that A3G molecules may 
represent a large complex while bound to RNA (190). Therefore, unstructured C-
Terminal regions of the Gag protein may sterically hinder the attachment of A3G 
molecules to the pre-existing Gag-RNA complex. Alternatively, C-terminal regions of 
Gag may be used to sterically hinder the attachment of A3G-RNA complexes to Gag 
molecules, preferentially selecting RNA that is not bound to A3G for packaging into 
virus particles. This certainly seems to be the case with HTLV-1, a retrovirus that 
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packages reduced levels of A3G and is therefore less susceptible to G-A hypermutation. 
HTLV-1 contains a long C-Terminal NC region with key acidic residues that inhibit A3G 
packaging, perhaps by the mechanisms outlined above (48). Therefore, although HTLV-1 
lacks a Vif protein, A3G is unsuccessful at completely inhibiting the infectivity of 
HTLV-1 particles. Data from Figure 7C and 7D suggest that the p6 region of HIV-1 Gag 
may perform a similar function to the C-Terminal region of HTLV-1 Gag, but less 
effectively.  
The model described above implies a structural relationship between A3G 
molecules, RNA, and Gag. It implies that there is no direct contact between Gag and 
A3G, this was shown above (Fig. 10). In addition, since RNA is known to induce the 
formation of A3G multimeric complexes, these may represent the functional form of 
A3G (190). As a result, the model further implies that A3G-RNA complexes are 
packaged into virus particles. This information would not only allow us to add greater 
depth to our model, but would also suggest a direction for experiments that would 
explore the earlier steps in trafficking of these complexes into particles. These questions 
are explored in Chapter III. 
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CHAPTER III 
 
APOBEC3G MULTIMERIC COMPLEXES IN VIRUS-LIKE PARTICLES 
 
Introduction 
Studies presented in Chapter II showed that amino acid residues within the 
nucleocapsid (NC) region of Gag that are important for the efficient incorporation of 
RNA, are also important for both the recruitment of APOBEC3G (A3G) to cellular 
membranes, and the packaging of A3G into virus-like particles (VLPs). Essentially, A3G 
is packaged into VLPs, and by extension, packaged into virus particles in a manner 
suggesting RNA-dependent incorporation. In addition, molecules of A3G have been 
observed to multimerize when binding to RNA, according to studies from yeast two-
hybrid experiments, immunoprecipitation assays, and 3D modeling of small angle x-ray 
scattering experiments (110, 190, 193). These results led me to hypothesize that A3G 
molecules interact closely with each other while binding to RNA strands within particles. 
I therefore set out to measure the presence of these A3G-RNA complexes within 
particles. Data from these experiments would enhance the model presented in Chapter II 
which suggested that Gag molecules bind to these RNA strands via the NC region of 
Gag, thereby causing the recruitment of A3G molecules into viral particles. This model 
was not universally accepted at the time these studies were initiated. In fact, intense 
controversy raged in the literature regarding whether A3G encapsidation into particles 
was driven by direct association with NC or by association with encapsidated RNA 
species as outlined in Chapter II. To address this issue, we used the technique of 
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Figure 11. Fluorescent Resonance Energy Transfer (FRET). (A) Schematic 
diagram contrasting the process of fluorescence to the process of FRET. (B) 
Efficiency of energy transfer from CFP to YFP as a function of the distance 
separating the fluorophores. 
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CFP/YFP Fluorescent Resonance Energy Transfer (FRET) to determine whether direct 
interactions were occurring between A3G molecules forming multimers and between 
A3G and Gag molecules. 
Förster or fluorescence resonance energy transfer (FRET) is a spectral technique 
used to measure nanometer distances between fluorescent molecules. First reported by 
Förster in 1948, this technique has experienced a rebirth in biological applications due to 
new fluorophores, optical methods, and instrumentation (69, 174). When a chromophore 
(dye or fluorophore) absorbs light it can dissipate this energy in one of three ways: 1) 
Dyes convert this energy to heat or vibrational energy, 2) fluorophores produce some heat 
but re-emit the remaining energy as light of a longer wavelength, or 3) either 
chromophore can transfer this energy to an acceptor molecule in close proximity, which 
may then emit the energy as light.  By definition, FRET is a non-radiative transfer of 
quantum energy from excited electrons of the donor molecule to ground state electrons in 
the acceptor molecule. The energy gained by the acceptor electrons must equal the energy 
lost by the donor electrons, therefore, the emission spectrum of the donor must overlap 
the absorbance spectrum of the acceptor fluorophores. This process, which is essentially 
coupled simultaneous energy state transitions, requires the molecules to be in very close 
proximity because the efficiency of energy transfer drops off quickly as the distance 
increases. In general, FRET is used to measure protein-protein interactions for 
fluorophores approximately within 20-60 Angstroms (Å) of each other (174). Proteins 
can be conjugated to dyes such as Cy3 and Cy5, small molecule tags such as Europium 
and allophycocyanin, or fused to variants of the green fluorescent protein (GFP) (67, 
114). The studies presented in this document focus on the latter strategy and utilize the 
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enhanced cyan fluorescent protein (CFP) as the donor fluorophore, and the enhanced 
yellow fluorescent protein (YFP) as the acceptor (shown in Figure 11A). The efficiency 
of energy transfer is described by the following equation, E = [1 + (r/r0)6]-1 where r is the 
distance between fluorophores, and r0 is the distance at which E = 50% or 49.2 Å (153). 
Therefore, the specific distance over which a FRET interaction greater than 5% can be 
detected for a CFP-YFP pair is theoretically less than 80 Å (Fig 11B). This is a relatively 
small distance considering the fact that a GFP molecule is 24 Å in diameter and 42 Å 
long (50, 151). Therefore, proteins that exhibit a FRET interaction are essentially 
touching. 
 Although to date FRET had not been used to measure A3G interactions, it was not 
a novel technique for the field of HIV-1. FRET assays have been used in the past to study 
the RNAse activity of reverse transcriptase, TAR-interacting proteins, nucleocapsid-
amino acid interactions, Rev multimerization, HIV-1 virion fusion, HIV-1 Gag-Gag 
interactions, and RSV Gag-Gag interactions (23, 41, 47, 100, 119, 136, 141). Therefore, 
to assess A3G-A3G interactions using FRET, the following fusion proteins were used 
due to their feasibility for use in live cells: APOBEC3G-CFP, APOBEC3G-YFP, Gag-
CFP, and Gag-YFP. FRET experiments in this thesis are performed in two different 
formats, FRET fluorometry and FRET microscopy, however, this chapter will focus on 
FRET fluorometry experiments. This particular technique was used to test the following 
predictions: 1) direct Gag-Gag interactions can be detected in cells and particles, 2) 
RNA-dependent APOBEC3G interactions can be found in cells and in particles, and 3) 
RNA mediated, but indirect, Gag-APOBEC3G interactions cannot be detected using 
FRET since the base-to-base distance of a nucleic acid is 70Å (83, 127, 142). The data 
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from these studies revealed that A3G complexes were packaged into Gag virus-like 
particles. However, despite the extensive biochemical evidence describing a Gag-
APOBEC3G interaction, we did not detect a direct FRET interaction between these two 
molecules, suggesting that an RNA bridge may mediate this interaction at a distance. 
Although the absence of a FRET signal can, in rare cases, be explained by incorrect 
fluorophore orientation, taken together with previous results, these data suggest that 
APOBEC3G is packaged into virions as an RNA-dependent multimer that is recruited to 
the plasma membrane and into budding virions by an RNA-mediated association with the 
HIV Gag protein. 
 
Materials and Methods 
 
Plasmid construction 
This study employed Gag and APOBEC3G expression constructs fused to 
variants of the codon-optimized version of CFP and YFP (Clonetech, Palo Alto, CA). 
The CFP and YFP expression vectors, the Gag expression constructs (47), and several of 
the APOBEC3G expression constructs were described in Chapter II. The APOBEC3G 
coding sequences for the YFP-A3G and A3G-CFP constructs were derived from the 
plasmid CEM15 that was obtained from Michael Malim (176). PCR cloning was used to 
amplify the APOBEC3G gene with an EcoRI site prior to the 5’ ATG and an XmaI site at 
the 3’ end. The amplified APOBEC3G gene was then ligated into pEYFP-C1 by 
digestion of the EcoRI and XmaI sites located within the multiple cloning region. This 
new construct was designated YFP-A3G. PCR cloning was used to amplify the CFP gene 
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from pECFP-N3 placing a SmaI site prior to the 5’ ATG and a NotI site at the 3’ end. The 
YFP gene in A3G-YFP was then removed by digestion with SmaI and NotI followed by 
gel purification. The amplified CFP gene was then ligated into the resulting plasmid to 
yield a new construct designated A3G-CFP.  
The oligonucleotides used in PCR amplifications for YFP-A3G construct  
CGGAATTCGATGAAGCCTCACTTCAGA-(F), TCCCCCGGGTCAGTTTT 
CCTGATT-(R); for A3G-CFP construct 
GGCCCGGGATCCATCGCCACCATGGTGAGCAAG-(F), GAGTCGC 
GGCCGCTTTACTTGTACAGCTCGTCCATGCCG-(R). 
 
Cell lines and transfections 
The human kidney cell line 293T was maintained in Dulbecco’s modified Eagle 
medium with 10% fetal bovine serum and antibiotics at 37°C in 5% CO2, and grown in 
100-cm2 tissue culture dishes. Transfections were performed by either the calcium 
phosphate-BBS transfection method or with Lipofectamine 2000 (Invitrogen, Carlsbad, 
Calif.), with 10 µg of total plasmid DNA unless otherwise stated. 
 
Production and purification of immature Gag virus-like particles (VLPs) 
Cell culture supernatants from transfected 293T cells were harvested 48 to 72 
hours post transfection, clarified by centrifugation, filtered through a 0.45-µm filter, and 
pelleted through a 20% sucrose cushion (100,000 × g for 2 h at 4°C). The pellets were 
resuspended in 1.0 mL of phosphate-buffered saline (PBS) and analyzed by scanning 
cuvette fluorometry using a tunable PTI cuvette fluorometer (Photon Tehnology 
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International, Lawrenceville, NJ). 
 
FRET analysis by scanning cuvette fluorometry 
Schematics of each of the experimental setups used in this chapter are depicted in 
Figure 12. Cells were harvested for analysis 24 hours following transfection. One 10 cm2 
dish of nearly confluent 293T cells was included for each experimental sample. Cells 
were washed in phosphate-buffered saline and whole cells or particles resuspended in 
PBS were analyzed. Each sample was kept at 4°C and analyzed by fluorometry in a PTI 
T-format scanning cuvette spectrofluorometer (Photon Tehnology international, 
Lawrenceville, N.J.). For analysis of CFP emission to compare the relative amount of 
CFP present, samples were excited at 433 nm, and performing an emission scan ranging 
from 460 to 550 nm. For analysis of YFP emission to compare the relative amount of 
YFP present, samples were exited at 513 nm, with an emission scan ranging from 524 to 
534 nm. For FRET analysis, samples were excited at 433 nm, and an emission scan 
ranging from 460 to 550 nm was obtained. For nuclease-treated FRET experiments, the 
cells were allowed to swell in hypotonic buffer (10 mM Tris-Cl pH 8.0, plus protease 
inhibitors) for 20 min on ice, and broken by dounce homogenization. The lysis buffer was 
supplemented with 60 µg/ml of RNAse A (Qiagen Inc., Valencia, CA) and 10 units/ml of 
RQ1 DNAse with buffer (Promega Corp., Madison, WI) while the control lysis buffer 
was treated with 200 units/ml of RNAse Inhibitor (New England Biolabs Inc., Beverly, 
MA). The lysates were then adjusted to 0.1 M NaCl, and the nuclei and unbroken cells 
were removed by centrifugation at 1000 × g for 10 min. Note that a constant amount of 
untagged Gag expression plasmid was co-transfected in each arm of this experiment. 
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Figure 12. APOBEC3G FRET fluorometry. Schematic depiction of a model for the 
structural relationship between Gag and APOBEC3G (A3G) molecules at the 
plasma membrane when detecting (A) Gag-Gag FRET, (B) A3G-A3G FRET, and 
(C) Gag-A3G FRET. 
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Data were collected from at least three different independent experiments for each 
expression construct.  
 
Results 
 
APOBEC3G multimers bind to RNA in cells and particles 
Fluorescence Resonance Energy Transfer (FRET) between CFP and YFP 
moieties have been used to detect interactions between Gag molecules in living cells. 
Briefly, stimulation of a CFP molecule at 433 nm normally leads to the emission of a 
strong peak at 475 nm, a shoulder from 490 – 510 nm, and a broad trail from 510 – 550 
nm (Fig. 13A, A3G-CFP emission spectra). YFP molecules are maximally stimulated at 
514 nm, therefore, if a YFP molecule is in contact (less than 100 angstrom) from an 
excited CFP molecule, the overlap in CFP emission and YFP excitation will allow energy 
transfer from the CFP to the YFP molecule. This will lead to the YFP molecule emitting 
at 527 nm. Therefore, to detect A3G-RNA-A3G complexes in live cells, A3G-YFP and 
A3G-CFP were coexpressed in 293T cells and the emission spectra of whole cells, 
resuspended in PBS, were obtained in a spectrofluorometer using an excitation 
wavelength of 433 nm. Cells expressing A3G-YFP and A3G-CFP exhibited a curve 
representative of efficient fluorescence energy transfer (Fig. 13A, blue squares), as did 
Gag-CFP and Gag-YFP (Fig. 13A, open squares), while cells expressing A3G-CFP and a 
control YFP resulted in a CFP emission peak with no YFP emission peak (Fig. 13A, open 
circles). Identical results were obtained with YFP-A3G (results not shown). Similar 
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levels of YFP emission were obtained upon YFP excitation for each experimental 
condition, indicating that the protein levels were similar (Fig. 13B). 
 To determine whether RNA is a necessary component of these APOBEC3G 
complexes, cell lysates from cells expressing A3G-YFP and A3G-CFP were prepared and 
treated with RNAse A and DNAse RQ1 while RNA in control lysates was preserved by 
the addition of RNAse inhibitor. Control lysates expressing A3G-YFP and A3G-CFP 
exhibited a curve representative of efficient fluorescence energy transfer (Fig. 13C, blue 
squares), while nuclease treated lysates resulted in a CFP emission peak with no YFP 
emission peak (Fig. 13C, open circles). The A3G-CFP emission curve remained 
unchanged by nuclease treatment (Fig. 13C, closed triangles, closed diamonds). The lack 
of FRET in the nuclease treated lysates was not a result of lower protein concentration or 
degradation since similar levels of YFP emission were obtained upon YFP excitation for 
each experimental condition (Fig. 13D). This establishes that FRET is an effective tool to 
measure the presence of APOBEC3G multimers bound to RNA, and that RNA is 
required for APOBEC3G multimerization. 
 We next employed A3G-CFP/A3G-YFP FRET to determine whether 
APOBEC3G is incorporated into particles as a multimeric complex bound to RNA. Gag 
VLPs were generated in cells expressing Gag, A3G-YFP, and A3G-CFP. The emission 
spectrum of these particles was obtained in a spectrofluorometer using an excitation 
wavelength of 433 nm. Particles containing A3G-CFP and A3G-YFP (Fig. 13E, open 
circles), or A3G-CFP and YFP-A3G (Fig. 13E, blue squares) exhibited a curve 
representative of efficient fluorescence energy transfer. However, particles containing 
A3G-CFP and a control YFP resulted in a CFP emission peak with no YFP emission 
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Figure 13. APOBEC3G is packaged as multimers that interact with RNA. (A) The 
indicated constructs were co-transfected into 293T cells. Cells were resuspended in 
PBS and read directly in a scanning quevette fluorometer. FRET was measured by 
stimulating the CFP fluorophore at 433 nm and the FRET peak was observed at 527 
nm. FRET curve for A3G-YFP /A3G-CFP (blue squares), GagCFP / GagYFP (open 
squares). pEYFP coexpressed with A3G-CFP (open circles). Closed triangles, 
GagCFP VLPs. (B) Relative levels of cellular YFP expression are shown for the 
experiment depicted in panel A, as determined by peak YFP output following 
excitation of cell lysates at 514 nm. (C) Cell lysates prepared by treatment with 
hypotonic buffer and dounce homoginization. Half of cell lysates were treated with 
RNAse A and DNAse RQ1 prior to FRET analysis while RNA in the control lysates 
were preserved with RNAse inhibitor. FRET curve for A3G-YFP / A3G-CFP (blue 
squares), loss of FRET in nuclease treated A3G-YFP / A3G-CFP lysates (open 
cicles). A3G-CFP curve (closed triangles) and treated (closed diamonds). (D) 
Relative levels of cellular YFP expression are shown for the experiment depicted in 
panel A, as determined by peak YFP output following excitation of cell lysates at 
514 nm. (E) Virus like particles (VLPs) created by coexpressing pVRC3900Gag 
with the indicated constructs in 293T cells. Supernatants were concentrated through 
a 20% sucrose cushion, resuspended in PBS and analyzed by scanning cuvette 
fluorometry. FRET curve for A3G-CFP / A3G-YFP (open circles) and A3G-CFP / 
YFP-A3G (blue boxes). A3G-CFP coexpressed with pEYFP (closed triangles). (F) 
Relative levels of virus like particle (VLP) YFP content are shown for the 
experiment depicted in panel C, as determined by peak YFP output following 
excitation of VLPs at 514 nm. Note that transfection of an untagged Gag expression 
construct was included in each of the transfections at a constant amount. 
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peak (Fig. 13E, closed triangles). Increased YFP over-expression was used in this 
experiment to increase the free YFP content of VLPs. We conclude that the FRET 
detected in Gag VLPs represents APOBEC3G multimers bound to RNA that have 
become incorporated in VLPs. 
 
Lack of support for a direct Gag-APOBEC3G interaction by FRET 
To further analyze the Gag-APOBEC3G interaction in living cells and particles, 
we asked whether we could detect a direct Gag-APOBEC3G interaction by FRET. Cells 
expressing Gag-YFP and Gag-CFP exhibited a curve representative of efficient 
fluorescence energy transfer (Fig. 14A, blue circles) as a positive control. In contrast, 
cells expressing Gag-YFP and A3G-CFP revealed a CFP emission peak with no YFP 
emission peak, indicating no FRET (Fig. 14A, open squares). Results with Gag-YFP and 
A3G-CFP were identical to the negative control of Gag-YFP co-expressed with CFP 
(Fig. 14A, closed triangles). Similar levels of YFP emission were obtained upon YFP 
excitation for each experimental condition, indicating that differential protein levels did 
not account for the differences in positive controls and the test molecules (Fig. 14B). 
 Gag VLPs were then generated in cells expressing Gag, Gag-CFP, and A3G-YFP. 
In the same system A3G-YFP was replaced by Gag-YFP as a FRET positive control and 
YFP-Mem (Clontech) as a FRET negative control. The emission spectrum of these 
particles was obtained in a spectrofluorometer using an excitation wavelength of 433 nm. 
Particles containing Gag-CFP and Gag-YFP exhibited a curve representative of efficient 
fluorescence energy transfer (Fig. 14C, blue circles), while particles containing Gag-CFP 
and A3G-YFP resulted in a CFP emission peak with no YFP FRET peak (Fig. 14C, open  
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Figure 14. Lack of FRET between APOBEC3G and Gag.  (A) The indicated 
constructs were co-transfected into 293T cells. Cells were resuspended in PBS and 
read directly in a scanning quevette fluorometer. FRET was measured by 
stimulating the CFP fluorophore at 433 nm and the FRET peak was observed at 527 
nm. FRET curve for Gag-YFP - Gag-CFP (blue circles). Gag-YFP coexpressed 
with A3G-CFP (open squares) and pECFP (closed triangles). (B) Relative levels of 
cellular YFP expression are shown for the experiment depicted in panel A, as 
determined by peak YFP output following excitation of cell lysates at 514 nm. (C) 
VLPs created by coexpressing the indicated constructs in 293T cells. Supernatants 
were concentrated through 20% sucrose cushion, resuspended in PBS and analyzed 
by scanning cuvette fluorometry. FRET curve for Gag-CFP / Gag-YFP (blue 
circles). Gag-CFP coexpressed with A3G-YFP (open squares) and pEYFP (closed 
triangles). (D) Relative levels of virus like particle (VLP) YFP content are shown 
for the experiment depicted in panel C, as determined by peak YFP output 
following excitation of VLPs at 514 nm. 
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squares). The lack of FRET in particles containing Gag-CFP and A3G-YFP was not due 
to lower concentrations of A3G-YFP in this experiment, as similar levels of YFP 
emission were obtained for each experimental condition (Fig. 14D). These results 
indicate that we were unable to detect direct interactions between Gag and APOBEC3G 
in cells or VLPs using this technique. Interpretation of these results must include 
recognition that a negative result in a CFP-YFP FRET assay does not rule out a direct 
interaction, as FRET can be dependent on both the position and orientation of the CFP 
and YFP molecules (54, 153). 
 
Discussion 
Together with results from the previous Chapter, my findings support an RNA-
dependent incorporation of multimeric APOBEC3G complexes into VLPs. First, in vitro 
interactions of APOBEC3G and the NC region of Gag were shown to be RNAse-
sensitive as reported by our lab and others (Chapter II). Secondly, we found that the 
incorporation of APOBEC3G into a series of serially truncated Gag protein constructs 
quantitatively correlated with the RNA-to-Gag ratio of the released particles (Chapter II). 
Finally, data from FRET studies in this chapter provide indirect evidence for a 
requirement for RNA in A3G packaging by revealing both that RNA is required for 
APOBEC3G-APOBEC3G interactions, and that these APOBEC3G multimers are 
subsequently packaged into VLPs. Opi et al. reported a monomeric APOBEC3G mutant 
(C97A) that is packaged into VLPs and is catalytically active, indicating that it retains the 
ability to bind to RNA (150). This suggests that A3G-RNA binding does not require 
multimerization, but rather, that monomeric or dimeric forms of A3G initially bind to 
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RNA forming a transition state that subsequently recruits additional A3G molecules, 
leading to the formation of a multimeric A3G complex. Why does A3G bother to 
multimerize if the monomeric form contains antiviral activity? It is tempting to speculate 
that multimerization may play a role in an aspect of enzyme function not yet described in 
sufficient detail such as the efficiency or kinetics of deamination. Nevertheless, the 
majority of APOBEC3G in cells is present in an RNAse-sensitive multimeric form (150). 
In addition, several reports have suggested that APOBEC3G binds to itself in cells (110, 
193) in an RNA-dependent manner (193) producing high molecular mass (HMM) 
complexes observed in activated T-cells and transfected 293T cells (27, 118). Therefore, 
in contrast to Opi et al. our FRET studies demonstrated that wild-type APOBEC3G 
multimers were incorporated into virions. In agreement, however, with previous reports, 
these oligomers were also detected in cell lysates and could be disrupted by RNAse 
treatment. These data demonstrate that APOBEC3G multimerizes on cellular or viral 
RNA, and that it is these APOBEC3G multimers, complexed with RNA, that are 
recruited into developing particles. It makes sense that these A3G complexes represent 
the enzymatically active enzyme during the reverse transcription process, as they are 
recruited directly into the viral core that becomes the location for reverse transcription 
following entry of the virus into a cell. 
Under the same experimental conditions in which APOBEC3G-APOBEC3G 
FRET was detected, and in which Gag-Gag FRET is readily detected, we failed to detect 
Gag-APOBEC3G FRET. Together with data from Chapter II this indicates that there is 
not a direct protein-protein interaction between Gag and APOBEC3G in cells or virions. 
While the unlikely possibility that most of the CFP and YFP tags on Gag and 
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APOBEC3G are simply held rigidly in a sub-optimal orientation for FRET does exist, the 
presence of a flexible linker region between both proteins and the fluorescent moieties 
should have minimized these potential orientation effects (54, 153). 
The data in this Chapter, in conjunction with current literature, can be used to 
refine the structural details of this model. The A3G monomer has recently been modeled 
after the APOBEC2 homodimer which forms a head-to-head tetramer 127 Å long (159, 
205). In agreement with these results, the nanostructure of RNAse treated A3G from cells 
shows a 140 Å rod approximately 100 kDa in size, indicative of an A3G dimer (190). The 
fluorophores in these head-to-head dimers would be 180 Å apart, and therefore 
undetectable by FRET. In the same study the nanostructure of A3G, untreated by RNAse, 
resembled a cylinder with two rods of A3G dimers packed neatly inside (190). This 
would place the fluorophores in direct apposition to each other, making this structure 
visible by FRET. Therefore, the limited structural evidence is in agreement with my 
analysis that multimeric forms of A3G in complex with RNA are packaged into particles, 
implying that A3G is packaged as a functional unit no smaller than a tetramer (i.e. 4, 8, or 
12 molecules). Supporting this notion was a recent analysis which indicated that the 
number of A3G molecules packaged into ∆vif virions produced from activated human 
peripheral blood mononuclear cells (PBMC) was between 3 and 11 molecules, suggesting 
that only one tetrameric A3G complex is actually required per virion for inhibition of 
replication (197). This enhanced view of my model for A3G packaging makes it clear 
that even small increases in A3G expression levels would provide significant antiviral 
properties in a patient. It is interesting that the large size of this A3G complex (~200Å × 
100Å) compared to HIV-1 Gag (85Å × 34Å) reinforces the idea that steric forces may 
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play a big role in the inhibition of A3G packaging by the C-terminal portion of HIV-1 
and HTLV-1 Gag molecules (148, 190). Nevertheless, and perhaps as a result of the 
relatively small number of A3G complexes packaged, their presence does not appear to 
disrupt particle assembly and seem to generate only subtle differences in virion 
morphology (11, 76, 149). Taken together, our findings support a model in which 
APOBEC3G multimers form on RNA species trafficking through the cytoplasm as they 
are recruited into the developing particle through interactions with NC. 
In order to confirm the hypothesis that the plasma membrane is truly a step in the 
trafficking of A3G multimeric complexes into particles, I decided to microscopically 
image these A3G complexes as they traffic into particles. Therefore, in Chapter III I 
developed microscopic techniques to observe this activity. 
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CHAPTER IV 
 
FLUORESCENT AND FRET IMAGING OF APOBEC3G COMPLEXES 
RECRUITED TO THE PLASMA MEMBRANE BY HIV-1 GAG 
 
Introduction 
The aim of Chapter III was to characterize APOBEC3G (A3G) complexes and 
A3G-Gag interactions using FRET analysis of whole cells and undisrupted particles. 
Although a direct A3G-Gag interaction was not detected, A3G-RNA complexes were 
found to exist in both cells and particles. Due to the fact that HIV-1 particle assembly 
occurs primarily at the plasma membrane, the next aim of my research was to analyze the 
recruitment of A3G complexes to the plasma membrane by Gag. Limited 
immunofluorescent studies were previously performed studying the native localization of 
A3G (131, 182) and its localization during co-expression of HIV-1 Gag (1, 55). Authors 
of these studies reported limited co-localization of A3G with Gag. However, recent and 
more detailed studies of native A3G localization in a variety of cell types suggested that 
these earlier studies were unable to show correct A3G subcellular localization (192, 193). 
Furthermore, studies describing the subcellular localization of A3G complexes in the 
absence and presence of Gag co-expression have been notably absent in the literature. To 
address this issue, I performed experiments employing a novel fluorescent resonance 
energy transfer (FRET) assay for the detection of A3G complexes in living cells. In these 
studies, a CFP donor-YFP acceptor approach to measure A3G-A3G interactions that are 
within 80 Å of each other (174). Microscopic visualization of FRET was accomplished 
by imaging the sample using YFP emission filters (527 nm) while stimulating the sample 
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with a CFP specific laser (405 nm) or filters (433 nm). The existence of FRET between 
two proteins in a sample was further verified in several cases by photobleaching the 
acceptor fluorophore (114). Photobleaching destroys the YFP in a FRET sample leading 
to a decrease in YFP emission, but also a corresponding increase in the CFP emission 
spectrum. Therefore, although previously FRET fluorometry was used to determine if 
FRET was occurring, in these experiments FRET microscopy was used to determine the 
location where a FRET interaction occurs. This approach showed that A3G-A3G 
multimers are detected in mRNA processing bodies (P-bodies), but additionally at the 
plasma membrane upon HIV-1 Gag expression. 
 
Materials and Methods 
 
Plasmids, cell lines, and transfections 
Plasmids used were described in Chapter II and Chapter III. The human cervix 
epithelial cell line HeLa was maintained in Dulbecco’s modified Eagle medium with 10% 
fetal bovine serum and antibiotics at 37°C in 5% CO2, and grown in MatTek tissue 
culture dishes for live cell imaging or chamber slides for fixation. Transfections were 
performed with Lipofectamine 2000 (Invitrogen, Carlsbad, Calif.), with 2 µg of total 
plasmid DNA unless otherwise stated. 
 
Fluorescence microscopic analysis of subcellular localization of A3G-YFP and 
Gag-CFP 
Live HeLa cells expressing A3G-YFP alone or together with Gag-CFP were 
examined using a Nikon TE2000 equipped with automated filter wheels, stage, z-axis 
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motor and digital camera. All images were obtained using the 63X objective; serial 
sectioning was performed using MetaMorph software (Molecular Devices) and 
deconvolution was performed using constrained iterative algorithms with Autoquant 
software package. For the images shown in Fig. 8F-H, a digital mirror device (Digital 
Diaphragm, Photonic Instruments, St. Charles, IL) and 488nm laser was used to 
specifically photobleach the internal regions of the cell surrounding bright cytoplasmic 
bodies of A3G-YFP. 
 
Fluorescence microscopic analysis of the subcellular localization of A3G-YFP 
and A3G-CFP FRET 
Live HeLa cells expressing A3G-YFP alone or together with A3G-CFP were 
examined using the 63X objective on a Nikon TE2000. FRET images were obtained by 
the sensitized emission method followed by deconvolution with a constrained iterative 
algorithm (MetaMorph Autoquant software package, Molecular Devices). Briefly, donor 
and acceptor constants were first generated by the following method. A CFP image and a 
raw FRET image (CFPexcitation/YFPemission) were obtained from cells expressing 
Gag-CFP alone, and a YFP image and a raw FRET image were obtained from cells 
expressing Gag-YFP alone. The pixel intensity in the raw FRET image was divided by 
the pixel intensity in the corresponding CFP image to yield the donor constant A = 0.78. 
This was repeated for YFP to yield the acceptor constant B = 0.11. These constants were 
then used to generate true FRET images from raw FRET images in the following way. 
Each cell was serially sectioned using MetaMorph software (Molecular Devices) for all 
three wavelengths (CFP, YFP, raw FRET). A FRET image was then generated for each 
z-plane using the following formula applied to each pixel: FRET = raw FRET – A*CFP – 
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B*YFP.  Finally, the same deconvoluted z plane was selected for the CFP, YFP, and 
FRET images and all were treated as follows. MetaMorph imaging software was used to 
set identical scaling for the YFP and CFP images; scaling of FRET images was set at 
50% of the YFP image display value, so that the dimmer FRET images are represented in 
Fig. 10 with similar intensities as the YFP and CFP images. Each set of 3 images in this 
figure (CFP/YFP/FRET) was treated in the same manner. Images were colorized as cyan 
or yellow, exported as RGB TIF files, and converted to CMYK images using Adobe 
Illustrator. 
 
FRET acceptor photobleaching and spectral analysis using laser confocal  
fluorescence microscopy 
HeLa cells were grown and transfected in cell culture treated chamber slides and 
imaged following fixation in 4% paraformaldehyde for 10 min. Images were obtained 
with a Zeiss LSM 510 laser scanning confocal microscope (Carl Zeiss Inc., Thornwood, 
N.Y.) equipped with a Meta multichannel detector, making pixel intensity quantitation 
possible over a range of emission wavelengths. Emission scans were obtained by use of 
Zeiss LSM software following stimulation with a 405 nm laser. The 514 nm laser was 
used to provide high-intensity pulses of light for photobleaching of YFP to specified 
regions of interest in the cell. A standard YFP excitation-emission picture was taken 
before and after the photobleaching. 
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Results 
 
APOBEC3G is recruited to the plasma membrane by Gag 
APOBEC3G has been described as diffuse in the cytoplasm of the cell but has 
recently been shown to collect in dense cytoplasmic bodies identified as mRNA 
processing (P) bodies by Wichroski and colleagues (193). We assessed the subcellular 
localization of APOBEC-YFP using widefield deconvolution fluorescence microscopy. 
Very bright, punctate collections of A3G-YFP were noted in the cytoplasm of most 
transfected cells, consistent with the report of Wichroski (Fig. 15A). Under these 
conditions, diffusely cytoplasmic APOBEC3G could only be visualized under conditions 
allowing saturation of pixels in P-bodies (Fig. 15B). We observed little evidence of 
APOBEC3G on the plasma membrane even in these overexposed images. When Gag-
CFP was co-expressed with A3G-YFP, a mixed pattern was observed. The most intense 
A3G-YFP signal was consistently present in P bodies, but a subset of cells demonstrated 
plasma membrane A3G-YFP signal (leftmost cell in panels 15D, 15E, and 15F). Note 
that as shown in the two rightmost cells in Fig. 15E, plasma membrane colocalization 
was not apparent in the majority of cells. When observed, however, the colocalization 
appeared in bright punctate patterns along the plasma membrane suggestive of sites of 
particle assembly, as indicated in Fig 15C (a higher magnification view of the cell in Fig. 
15E).  In many cells in which A3G-YFP was expressed, the extreme brightness of the P 
body did not allow assessment of potential colocalization with Gag at the plasma 
membrane. To better examine these cells, we performed laser photobleaching of the 
interior region surrounding the P bodies, followed by a longer exposure of the remaining 
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Figure 15. Subcellular localization of Gag and A3G-YFP. A3G-YFP and Gag-CFP 
were expressed in HeLa cells and visualized by optical sectioning on a Nikon TE2000 
microscope equipped with an automated stage and z-axis motor, followed by 
deconvolution using constrained-iterative algorithms. (A) Bright cytoplasmic 
collections of A3G-YFP consistent with P body localization. (B) Longer exposure 
time allowing saturation of P body signal reveals diffuse cytoplasmic A3G-YFP 
signal. (C) Plasma membrane colocalization of Gag signal (red) and A3G-YFP 
(green); inset from leftmost cell in Fig. 8F. (D-F) Single channel images and image 
overlay indicating Gag signal (red), A3G-YFP signal (green). (G-I) Similar technique 
as in D-F above, but bright collections of A3G-YFP in interior of cell were bleached 
with 488nm laser to diminish brightness and facilitate visualization of plasma 
membrane fluorescence. 
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fluorescent signal in the cell. Fig. 15G-I represents one such cell in which Gag-CFP is in 
red, A3G-YFP is shown in green, and plasma membrane colocalization is demonstrated 
as yellow pixels in 15H. Note that there is little apparent colocalization of Gag in the P 
bodies, but there appears to be recruitment of A3G-YFP from the cytoplasm to punctate 
spots on the plasma membrane. We conclude from these data that although overexpressed 
A3G-YFP appears most intensely in P bodies, a subset of A3G-YFP is recruited to the 
plasma membrane where it colocalizes with Gag in the developing particle. 
 
APOBEC3G-APOBEC3G interactions were observed in structures consistent with 
P bodies by confocal spectral analysis 
The laser confocal microscope allows the spectral separation of light emitted from 
selected pixels when equipped with a multichannel detector.  To further establish the 
presence of A3G-A3G FRET and to determine the localization of this FRET we analyzed 
the emission spectrum from different regions of the cell before and after photobleaching 
the A3G-YFP acceptor molecule. If a transfer of energy were occurring between the CFP 
and YFP molecules, the destruction of YFP absorption by photobleaching would lead to 
retention of energy by the CFP molecules and an increase in CFP fluorescence. We had 
used spectral analysis on the Zeiss LSM510 Meta confocal microscope previously to 
demonstrate the interaction of Gag-CFP and Gag-YFP on the plasma membrane (47). We 
repeated this analysis, using Gag-CFP and Gag-YFP as positive controls in parallel with 
our APOBEC test constructs. Briefly, HeLa cells expressing Gag-CFP and Gag-YFP 
were imaged showing YFP localization before and after bleaching of the YFP at 514 nm 
(Fig. 16A-B). An emission scan of the cells in 16A-B was performed using excitation of 
CFP at 405 nm. The spectra from a bleached section of the plasma membrane (region of  
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Figure 16. Analysis of A3G-A3G interactions by confocal microscopy and 
fluorescence acceptor photobleaching. (A) Gag-CFP and Gag-YFP were 
cotransfected in HeLa cells, and images were obtained with a Zeiss LSM 510-Meta 
confocal microscope. The image represents YFP excitation-emission before 
photobleaching. The arrows indicate the selected plasma membrane region of 
interest to be bleached (ROI1) and the control region (ROI2). (B) The same cell as 
that shown in panel A is depicted following photobleaching at 514 nm in the 
indicated square. (C) Emission scans were obtained from region of interest 1, with 
excitation at 405 nm (CFP excitation), before (dashed line) and after (solid line) 
photobleaching of cells shown in panel A and B. (D) Emission scans were obtained 
from the control region of interest 2, with excitation at 405 nm, before (dashed line) 
and after (solid line) photobleaching of cells shown in panel A and B. (E) A3G-CFP 
and A3G-YFP were cotransfected in HeLa cells and the image shows the 
distribution of A3G-YFP prior to bleaching. The regions of interest selected are 
consistent with P body localization. (F) The same cell as that shown in panel E is 
depicted after photobleaching of the indicated square. (G) Spectra obtained from 
ROI1 before (dashed line) and after (solid line) photobleaching from cells shown in 
panel E and F. (H) Spectra obtained from ROI2 before (dashed line) and after (solid 
line) photobleaching from cells shown in panel E and F. Scale bar represents 10 
micrometers. 
 
 83 
 
 84 
interest 1) revealed that after bleaching, the YFP peak at 530 nm was reduced while the 
CFP peak at 475 nm increased in fluorescence (Fig. 16C). The emission spectra from a 
control region of the plasma membrane (region of interest 2) remained unchanged (Fig. 
16D).  This confirms the existence of FRET between Gag-CFP and Gag-YFP molecules 
on the plasma membrane. Next, we employed this technique to determine the presence of 
a FRET interaction between A3G-CFP and A3G-YFP in structures consistent with P 
body subcellular localization. Figure 16E-F shows the localization of A3G-YFP in these 
cells before and after bleaching the region of interest 1 (ROI1). The emission spectra 
from pixels contained within the P body at ROI 1 reveal that the decrease in the YFP 
peak following bleaching is accompanied by a significant increase in the CFP peak (Fig. 
16G). P body pixels in the nearby but unbleached region of interest 2 show unchanged 
spectra (Fig. H). Bleached cytoplasmic locations close to ROI1 exhibit neither a FRET 
peak nor an increase in CFP fluorescence following bleaching (data not shown). This 
confirms that A3G-A3G interactions can be observed by FRET, and occur primarily in P 
bodies. 
 
APOBEC3G multimers are observed in P bodies and at the plasma membrane 
following Gag expression 
In order to image the subcellular location of A3G-A3G interactions during Gag 
expression, we next employed FRET microscopy in living cells. Using distinct filter sets, 
we obtained individual CFP, YFP, and CFP-YFP (FRET) images, and corrected each 
FRET image for donor bleedthrough and acceptor cross-stimulation using an algorithm as 
described in Materials and Methods. Obtaining true FRET images using filter sets is 
complicated, even with the best filters and software algorithms, so we included known 
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positive controls that were treated identically to the APOBEC3G expression experiments. 
Controls included HeLa cells expressing Gag-CFP alone (Fig. 17A-C), and cells 
expressing Gag-YFP alone  (Fig. 17D-F). These two negative controls were critical to 
establish that bleedthrough and cross-stimulation from CFP and YFP respectively can 
effectively be measured and subtracted from the final FRET image. We next employed 
this technique to examine the location of FRET in cells expressing Gag-CFP and Gag-
YFP. Consistent with findings in Figure 16A-D and our previously published findings 
(47) Gag-Gag FRET was detected at the plasma membrane and at distinct intracellular 
puncta (Fig. 17I). Finally, we employed this assay to observe the locations of A3G-A3G 
FRET with and without Gag expression. Consistent with the results from Figure 16E-H, 
cells expressing A3G-CFP and A3G-YFP exhibit FRET only in the P bodies (Fig. 17J-L, 
arrows). However, the expression of Gag together with A3G-CFP and A3G-YFP resulted 
in detectable FRET signal at the plasma membrane in a subset of cells examined (Fig. 
17M-O). This is consistent with a model in which Gag recruits A3G-RNA-A3G 
multimers to the plasma membrane. 
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Figure 17. Subcellular localization of A3G-CFP and A3G-YFP FRET. (A-C) CFP, 
YFP, and FRET images obtained from HeLa cells expressing Gag-CFP (negative 
control). (D-F) CFP, YFP, and FRET images from cells expressing Gag-YFP 
(negative control). (G-I) CFP, YFP, and FRET images from cells expressing both 
Gag-CFP and Gag-YFP. (J-L) CFP, YFP, and FRET images from cells expressing 
A3G-CFP and A3G-YFP (without Gag). Structures consistent with the subcellular 
localization of P bodies exhibit FRET. (M-O) CFP, YFP, and FRET images from a 
cell expressing Gag, A3G-CFP, and A3G-YFP. In addition to P body FRET, 
plasma membrane FRET and a low level of cytoplasmic FRET is shown. Scale bar 
represents 10 micrometers. 
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Discussion 
 A unique aspect of this study was the finding that Gag recruits APOBEC3G to the 
plasma membrane. Three lines of evidence support this finding. First, membrane flotation 
data indicated a redistribution of APOBEC3G to cellular membranes following Gag 
expression (Chapter II). Second, APOBEC3G colocalized with Gag at the plasma 
membrane. Finally, APOBEC3G-RNA-APOBEC3G complexes, which were found 
predominantly in P bodies in the absence of Gag expression, were detected at the plasma 
membrane in cells cotransfected with Gag. Recruitment of APOBEC3G to the plasma 
membrane is somewhat intuitive, since Gag is responsible for the incorporation of RNA 
and APOBEC3G, and Gag must interact with membranes for intracellular trafficking and 
budding from the cell. It is tempting to speculate that Gag recruits APOBEC3G at early 
stages following translation on cytoplasmic ribosomes, in conjunction with viral genomic 
RNA. In this model, a Gag/RNA/APOBEC3G complex would then traffic along 
endosomal pathways to the plasma membrane for budding (or to the MVB in the infected 
macrophage). Despite the attractiveness of this model, we were not able to demonstrate 
significant colocalization of Gag and APOBEC3G within the cytoplasm of the cell, 
particularly in the punctate cytoplasmic collections reported by others to be P bodies 
(192, 193). However, we did note occasional faint colocalization at these sites (data not 
shown). Colocalization of Gag with APOBEC3G at the plasma membrane was detected, 
especially in cells in which the intensely bright signal from P bodies was reduced by 
photobleaching. It is possible that the population of APOBEC3G present in the dense P 
bodies is itself incorporated into particles, but perhaps more likely that Gag recruits 
APOBEC3G from the cytoplasmic pool that then multimerizes on the viral RNA. Kozak 
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et al. recently reported the binding of APOBEC3G to a pool of RNA that reversibly 
shuttles between polysomes and stress granules (117); it may be this pool that is 
packaged in the VLP in the absence of HIV genomic RNA. We acknowledge the caveat 
that the intensity of the signal observed in our microscopic studies result from 
overexpression of APOBEC3G fused to YFP rather than endogenous APOBEC3G. 
However, these results are consistent with others who have reported very intense 
cytoplasmic (P-body) collections of both endogenous and over-expressed APOBEC3G 
(192, 193). 
One important caveat to this study was the difficulty we had observing plasma 
membrane localization of A3G in each and every cell. Perhaps one reason for this 
difficulty is the relatively low efficiency of A3G incorporation into particles. One study 
showed that as little as 3-11 A3G molecules are incorporated into each virion while, by 
comparison, each budding particle contains between 1500 to 5000 Gag molecules (16, 
148, 197). Although it is known that this number can be increased by higher A3G 
concentrations (24), over-expression in my studies resulted in only 10% of all A3G 
synthesized by the cell being incorporated into particles (Figure 5B). Therefore, one 
might expect to find less than 10% of all cellular A3G to be found on the plasma 
membrane of a cell at any given time point. In fact, other authors have noted similar 
limitations in their studies (55). Nevertheless, further study is required to determine 
exactly why more prominent plasma membrane localization of A3G is not found on a 
higher proportion of cells. 
 The recruitment of A3G to the plasma membrane by Gag is a significant event 
because it is necessary for A3G to traffic through this location prior to getting into 
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particles. In Chapter II I demonstrated that the basic linker region of Gag was critical for 
causing the recruitment of A3G to all cellular membranes. The experiments in this 
chapter were necessary to show that this recruitment could be observed specifically at the 
plasma membrane. Although this effect was not demonstrated for the whole panel of Gag 
mutants, the biochemical data indicate that constructs lacking basic linker region of Gag 
would not recruit any more A3G to the plasma membrane than the negative control. The 
most important way in which these findings extend our understanding of A3G function is 
a determination of the location of A3G multimeric complexes during particle assembly. 
The discovery in Chapter III that this multimeric form of A3G represents the population 
packaged into particles indicates the importance of the intracellular trafficking of this 
form of A3G. My experiments showed that these complexes are observed at the plasma 
membrane along with Gag, demonstrating that A3G multimerize onto RNA at the plasma 
membrane or prior to trafficking to the plasma membrane. However, further studies need 
to be conducted to determine where in the cell multimerization takes place, whether it 
occurs on RNA species before or after they are bound to Gag, and the exact function that 
A3G multimerization plays in facilitating its antiviral properties. 
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CHAPTER V 
 
CELLULAR TRAFFICKING OF HIV-1 GENOMIC RNA 
 
Introduction 
 HIV genomic RNA molecules are synthesized in the nucleus but travel to sites of 
virus assembly following nuclear export through the Chromosome Region Maintenance 1 
(Crm1) mediated pathway (9, 198). The nucleocapsid (NC) region of the HIV-1 Gag 
molecule specifically binds to the genomic RNA, facilitating its packaging into virus 
particles. However, the route taken by HIV RNA to the plasma membrane, and the 
specific role that Gag plays in its trafficking is not understood. Certain outstanding and 
important questions remain, for example: Does Gag bind to genomic RNA prior to its 
arrival at the plasma membrane? Where does this initial interaction between Gag and 
genomic HIV RNA take place? Which steps of RNA trafficking to the plasma membrane 
require Gag, and which steps are Gag-independent? In order to answer these questions, it 
is necessary to physically observe the microscopic subcellular localization of HIV 
genomic RNA as it moves from the nucleus to the plasma membrane, and compare it to 
the subcellular localization of Gag as assembly takes place. One way these experimental 
goals can be accomplished by using the MS2 RNA labeling system, which involves the 
fluorescent labeling of genomic viral RNA during HIV assembly (12). 
 MS2 is a bacteriophage with an RNA genome, which is packaged into phage 
particles through binding of the MS2 coat protein to an RNA stem-loop binding site 
(154). Therefore, the MS2 system which is used for the fluorescent labeling of RNA 
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contains two components: 1) a non-dimerizing MS2 coat protein fused to a fluorescent 
molecule (example: GFP) and a nuclear localization signal (NLS), 2) the RNA of interest 
(reporter RNA) fused to several repeats of the RNA-binding site for the MS2 coat protein 
(4, 7, 21, 58, 96, 162, 203). Expression of the MS2-GFP-NLS (component 1) produces an 
intense nuclear fluorescence. However, co-expression of both constructs should cause 
some of the MS2-GFP-NLS to be transported into the cytoplasm together with the 
reporter RNA. As a result, reporter RNA trafficking can be examined by following 
cytoplasmic fluorescence. The experiments described in this chapter focus on the 
development and characterization of such a system designed to observe the export, 
trafficking, and encapsidation of HIV genomic RNA into virus particles. The components 
of the system involves the MS2 coat protein fused to several different fluorescent 
proteins, and the MS2 RNA stem loops fused to both the LTR driven NL4-3 provirus and 
a CMV driven RNA species used as an over-expression positive control. 
 
Materials and Methods 
 
Plasmid Construction 
The fluorescent tag fusion protein plasmids were created in three steps. The MS2 
coat protein was first cloned into pcDNA3.1, each fluoroscent protein (FP) was then 
cloned into pcDNA3.1 with an adjoining NLS, and finally each FP-NLS sequence was 
transferred into the plasmid containing the MS2 coat protein. Specifically, PCR cloning 
was used to amplify the MS2 coat protein gene from the polII-MS2-YFP plasmid 
(received from the Singer lab via Richard Sutton) by placing a BamHI site prior to the 5’ 
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ATG and an XhoI site at the 3’ end. The amplified MS2 gene was then ligated into 
pcDNA3.1 to yield a new construct designated pMS2. The oligonucleotides used in the 
PCR amplifications were AGGATCCATGGCTTCTAAC-(F) and 
TCTCGAGGTAGATGCCGGA-(R). PCR cloning was then used to amplify the 
mCherry, mOrange, Venus, and Cerulean genes by placing an XhoI site prior to the 5’ 
ATG and an XbaI-SV40 NLS sequence at the 3’ end. The amplified fluorescent protein 
genes were then ligated into pcDNA3.1 to yield new constructs designated mCherry-
NLS, mOrange-NLS, Venus-NLS, and Cerulean-NLS respectively. The oligonucleotides 
used in the PCR amplifications were ACTCGAGATGGTGAGCAAG-(F) and  
TTCTAGATTATACCTTTCTCTTCTTTTTTGGCATCTTGTACAGCTCGTC-(R). 
Finally, the fluorescent protein sequences were extracted from the Fluorescent Protein-
NLS plasmids by restriction digestion of the XhoI and XbaI sites flanking these genes. 
The purified products were then ligated into the pMS2 vector creating the constructs 
termed MS2-Cherry-NLS, MS2-Orange-NLS, MS2-Venus-NLS, and MS2-Ceru-NLS. 
These constructs were verified by restriction digest of selected clones. 
The MS2-PAGFP-NLS construct was created by a modification of the strategy 
described above. Briefly, PCR cloning was used to amplify the photoactivatable green 
fluorescent protein (PAGFP) gene by placing an XhoI site prior to the 5’ ATG and an 
XbaI-SV40 NLS sequence at the 3’ end as described above. The amplified fluorescent 
protein gene was then ligated directly into the pMS2 vector creating the construct termed 
MS2-PAGFP. 
The mCherry(-) construct was created by using PCR cloning to amplify the 
mCherry gene by placing an XhoI site prior to the 5’ ATG and a NotI site at the 3’ end. 
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The amplified fluorescent protein gene was then ligated into pcDNA3.1(-) and verified 
by restriction digest of selected clones. The oligonucleotides used in PCR amplifications 
were ACTCGAGATGGTGAGCAAG-(F) and 
GAGTCGCGGCCGCTTTACTTGTACAGCTCGTCCATGCCG-(R). 
The Cherry-6X and Cherry-6Xa constructs were created by the following 
strategy. First, the mCherry(-) plasmid was digested with BamHI and purified. Six MS2 
stem loops were then extracted from the MS2-6X plasmid (obtained from the Singer lab 
through Gary Bassell) by digestion with BamHI and BglII, followed by a gel purification 
step. The stem loops were then ligated into mCherry(-) creating two possible orientations: 
The forward orientation termed Cherry-6X, and the reverse orientation termed Cherry-
6Xa. Both constructs were digested with BamHI and purified. Six MS2 stem loops were 
again extracted from the MS2-6X plasmid by digestion with BamHI and BglII, followed 
by a gel purification step. The stem loops were then ligated into both the Cherry-6X and 
Cherry-6Xa plasmids, creating two possible orientations for each: The forward 
orientation of the six additional stem loops in Cherry-6X created the construct termed 
Cherry-12X, while the reverse orientation of the six additional stem loops in Cherry-6Xa 
created the construct termed Cherry-12Xa. 
Creation of NL4-3∆Env-6X and NL4-3∆Env-12X occurred in four steps. First, 
the NotI and EcoRI sites flanking the 1020 XbaI site in pEYFP were digested, the 
overhangs were filled in using Klenow polymerase, and the blunt ends were then ligated 
to create the pEYFP∆Xba transfer vector. Secondly, the mCherry sequence was 
eliminated from Cherry-6Xa and Cherry-12Xa by digestion with XhoI and EcoRI, the 
overhangs were filled in using Klenow polymerase, and the blunt ends were then ligated 
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to create pc6Xa and pc12Xa. Next, the pEYFP∆Xba construct was digested with XbaI 
and BamHI and purified. Stem-loop sequences in pc6Xa and pc12Xa were extracted by 
digestion with NheI and BamHI. These stem-loops were then ligated into pEYFP∆Xba 
creating p6Xa-EYFP and p12Xa-EYFP. Finally, NL4-3∆Env was digested with AgeI and 
SbfI and purified, eliminating a 640 bp region of RT. Stem loop sequences were then 
extracted from p6Xa-EYFP and p12Xa-EYFP by digestion with AgeI and SbfI, and then 
ligated into NL4-3∆Env creating the constructs NL4-3∆Env-6X and NL4-3∆Env-12X. 
 
Cell lines, and transfections 
The human cervix epithelial cell line HeLa was maintained in Dulbecco’s 
modified Eagle medium with 10% fetal bovine serum and antibiotics at 37°C in 5% CO2, 
and grown in MatTek tissue culture dishes for live cell imaging or chamber slides for 
fixation. Transfections were performed with Lipofectamine 2000 (Invitrogen, Carlsbad, 
Calif.), using 2 µg of total plasmid DNA unless otherwise stated. 
 
Fluorescence microscopic analysis 
Live HeLa cells were examined using a Nikon TE2000 equipped with automated 
filter wheels, stage, z-axis motor and digital camera. All images were obtained using the 
63X objective. 
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Results 
 
Experimental strategy and constructs 
 In order to track the movement of the reporter RNAs from the nucleus to the 
cytoplasm, I created five MS2-fluorescent tags to label the RNA, and we obtained one 
MS2-fluorescent tag protein, polII-MS2-YFP, from the Singer Lab. Figure 18A 
schematically depicts the structure of these fusion proteins, and they are listed in Table 1 
as follows: 1) polII-MS2-YFP, 2) MS2- PAGFP-NLS, 3) MS2-Ceru-NLS, 4) MS2-
Venus-NLS, 5) MS2-Cherry-NLS, and 6) MS2-Orange-NLS. The polII-MS2-YFP 
construct was obtained first and therefore used in the initial experiments. The 
photoactivatable GFP – MS2 fusion protein (MS2-PAGFP-NLS) was created to pulse 
label nuclear proteins and observe the egress of RNA that occurs only after the nuclear 
labeling event. The Venus and Cerulean - MS2 fusion proteins were created to look at 
FRET interactions between RNA and Gag, while the mCherry and mOrange - MS2 
fusion proteins were created to provide a selection of alternative colors for visualizing 
RNA export. Data will be presented in the following section for polII-MS2-YFP, MS2-
PAGFP-NLS, and MS2-Cherry-NLS.  
The second part of the system consists of a series of two over-expression RNAs, and two 
modified retroviral RNAs engineered to contain the MS2 binding sites, termed Cherry-
6X, Cherry-12X, NL4-3∆Env-6X, and NL4-3∆Env-12X respectively. Finally, one 
overexpression RNA lacking MS2 binding sites was created as a negative control, termed 
Cherry(-). Figure 18B schematically depicts Cherry-6X, while Figure 18C schematically 
depicts NL4-3∆Env-6X. Cherry-12X and NL4-3∆Env-12X contain 12 MS2 binding site  
 97 
 
Figure 18. A system for real time RNA tracking using MS2-fluorescent protein 
labeling. (A) Schematic depiction of an MS2-YFP-NLS fusion protein. Several 
versions with different fluorescent moieties have been constructed and are listed in 
Table 1. (B) Schematic depiction of the positive control, Cherry-6X reporter RNA. 
RNA secondary structures are listed above, open reading frames are listed below. (C) 
Schematic depiction of the NL4-3∆Env-6X reporter RNA. RNA secondary structures 
are listed above, open reading frames are listed below. 
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Table 1. Reporter RNA and fluorescent tag constructs for live cell RNA imaging.  
Name Description 
polII-MS2-YFP Obtained from Singer lab via Dr. Sutton. Contains a polII promoter and an MS2-YFP-NLS fusion protein. 
MS2-PAGFP-NLS 
(Photoactivatable 
GFP) 
Identical to Fig. 18A except the fluorescent moiety is the 
photoactivatable green fluorescent protein. MS2-PAGFP-NLS is 
designed to be exported from the nucleus when attached to a 
reporter RNA to allow cytoplasmic visualization of subcellular 
RNA trafficking. Photoactivation allows pulse-chase experiments 
to eliminate potential widespread background fluorescence. 
MS2-Ceru-NLS 
Identical to Fig. 18A except the fluorescent moiety is the Cerulean 
version of the cyan fluorescent protein. MS2-Ceru-NLS is 
designed to be exported from the nucleus when attached to a 
reporter RNA to allow cytoplasmic visualization of subcellular 
RNA trafficking. 
MS2-Venus-NLS 
Identical to Fig. 18A except the fluorescent moiety is the Venus 
version of the yellow fluorescent protein. Designed to be used as 
above. 
MS2-Cherry-NLS Identical to Fig. 18A except the fluorescent moiety is the mCherry fluorescent protein. Designed to be used as above. 
MS2-Orange-NLS Identical to Fig. 18A except the fluorescent moiety is the mOrange fluorescent protein. Designed to be used as above. 
Cherry-6X Identical to Fig. 18B. Cherry-6X is designed to express soluble cytoplasmic mCherry as a marker for reporter RNA expression. 
Cherry-12X Identical to Fig. 18B except 12 stem loop repeats are used instead of 6. Designed to be used as above. 
mCherry(-) Contains the mCherry sequence cloned into pcDNA3.1(-). Used to create the Cherry-6X and Cherry-12X constructs. 
NL4-3∆Env-6X 
Identical to Fig. 18C. This construct contains a premature stop 
codon in env for safe handling. Designed to produce a retroviral 
HIV reporter RNA that can be tagged and followed as it traffics to 
sites of assembly. 
NL4-3∆Env-12X Identical to Fig. 18C except 12 stem loop repeats are used instead of 6. Designed to be used as described above. 
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stem loops but are otherwise identical to the depictions in Figure 18B and 18C 
respectively. These reporter RNAs are listed in Table 1. In the Cherry overexpression 
reporter RNA constructs the MS2 binding site stem loops were engineered between the 
mCherry stop codon and the polyadenylation sequence (Figure 18B). These constructs 
allow the selection of cells for microscopic analysis in which reporter RNA expression 
can be confirmed by observing mCherry fluorescence. The retroviral RNA reporter 
constructs actually contain several RNA secondary structures both naturally occurring 
and artificially engineered. TAR, psi, and the RRE occur naturally in all HIV-1 and their 
functions are reviewed in Chapter I. However, in these retroviral RNA reporter 
constructs, the MS2 binding sites replace a large section of the RT gene, which ensures 
that only full length genomic RNA will be fluorescently labeled. In the following section 
data will be presented on the Cherry-6X construct. 
 Characterization of the MS2 RNA tracking system involves verifying three main 
functions. First, the MS2-fluorescent tags should localize exclusively to the nucleus when 
expressed alone. Secondly, co-expression of the MS2-fluorescent tags with the positive 
control reporter RNA containing the MS2 binding sites should produce export of the 
MS2-fluorescent tags into the cytoplasm. Finally, co-expression of the MS2-fluorescent 
tags with the retroviral reporter RNA containing the MS2 binding sites should produce 
export of the MS2-fluorescent tags into the cytoplasm and ultimately to sites of retroviral 
assembly such as the plasma membrane. Therefore, the ability of this system to 
accurately track the movement of retroviral RNA from the nucleus and into particles will 
be assessed based on these parameters. 
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MS2-Fluorescent tags localize to the nucleus 
 The localization of the MS2-fluorescent tags to the nucleus was tested by the 
independent expression of each construct in a human osteosarcoma cell line (Hos). 
Expression of MS2-PAGFP-NLS yielded a very low signal (Figure 19A) that was 
significantly enhanced by photoactivation of the whole cell (Figure 19B). The activated 
GFP signal was localized predominantly to the nucleus. Expression of polII-MS2-YFP 
and MS2-Cherry-NLS in Hos cells also showed a predominantly nuclear localization 
(Figure 19C and D respectively).  
 
MS2-Fluorescent tags localize to the cytoplasm upon reporter RNA expression 
 Subcellular localization of the MS2-fluorescent tags to the cytoplasm was tested 
by co- expression of polII-MS2-YFP with Cherry-12X. Expression of polII-MS2-YFP 
with the negative control mCherry(-) produces an exclusively nuclear localization 
identical to independent expression of polII-MS2-YFP (Figure 20A). However, 
expression of polII-MS2-YFP simultaneously with Cherry-6X produces an intense 
diffuse cytoplasmic localization of the fluorescent tag consistent with the expected 
localization of diffuse cellular RNA (Figure 20B). Similar results were obtained when 
using MS2-Venus-NLS (C – D) and MS2-Ceru-NLS (E – F). This data indicates that the 
MS2-fluorescent fusion proteins bind to the stem loop elements and thus get exported 
into the cytoplasm. 
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Figure 19. MS2-fluorescent molecules localize to the nucleus. (A) MS2-PAGFP-NLS 
expression prior to photoactivation. (B) MS2-PAGFP-NLS has a nuclear localization 
after photoactivation. (C) polII-MS2-YFP and (D) MS2-Cherry-NLS exhibit nuclear 
localization when expressed alone.  
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Figure 20. MS2-fluorescent molecules are exported from the nucleus by reporter 
RNA. (A) PolII-MS2-YFP, (C) MS2-Venus-NLS, and (E) MS2-Ceru-NLS are 
retained in the nucleus when co-expressed with Cherry(-). (B) PolII-MS2-YFP, (D) 
MS2-Venus-NLS, and (F) MS2-Ceru-NLS are exported into the cytoplasm when 
co-expressed with Cherry-6X. 
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Localization of MS2-Fluorescent tags to sites of assembly upon retroviral reporter  
RNA expression 
 NL4-3∆Env-6X and NL4-3∆Env-12X are in the final stage of cloning. This 
project is currently being continued by others in the Spearman lab. 
 
Discussion 
 A major gap exists in the field of HIV relating to the events that take place after 
genomic RNA leaves the nucleus. In fact, without correct trafficking and incorporation of 
the virus’ genetic material, viral particles would be completely incapable of infecting new 
cells. Therefore, understanding the fundamental nature of how viral genomic RNA 
travels to sites of assembly is critical to our understanding of how, ultimately, to disrupt 
this process. 
 Several obstacles present themselves traditionally when trying to determine the 
viral genomic egress pathway. First, biochemical studies that fractionate whole 
populations of cells lose the precise information gained from observing a single cell. 
Secondly, biochemical fractionation studies are also not precise enough to separate 
multiple and overlapping subcellular compartments while maintaining native protein-
protein interactions. Thirdly, although the application of microscopic techniques to 
protein trafficking studies has been greatly facilitated by the use of fluorescent fusion 
proteins as illustrated in Chapters II - IV, a similar technique to label RNA in live cells 
has not been available as in-situ RNA hybridization techniques are primarily used to 
microscopically image cellular RNA in fixed samples. A technique that has emerged 
recently as another novel method of imaging RNA movement in live cells is the use of a 
molecular beacon conjugated to an oligonucleotide probe that allows the visualization of 
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only hybridized probes (15, 134, 135, 166). However, we chose to pursue the 
development of the two-part MS2-fluorescent labeling system for RNA visualization. 
This new and exciting technique provides several advantages that overcome many of the 
limitations noted above. First, this approach can be used in living cells and is easily 
adapted to DNA transfection techniques. Secondly, this technique can be used to observe 
a single RNA molecule moving in single cell, providing precise information about RNA 
localization at specific time points. Lastly, it lends itself to the imaging of RNA as it 
moves through overlapping subcellular compartments, provided the correct subcellular 
markers are employed. Therefore, the data presented here provide the framework for a 
tractable system that can be used to determine detailed steps in the trafficking and 
assembly of retroviral RNA. 
 The MS2-fluorescent protein RNA tracking system is not without its limitations 
however. Two of the most significant but contradictory limitations are nuclear leakiness 
to MS2 fusion proteins, and the artificial nuclear retention of labeled RNA due to the 
attachment of multiple NLS to its secondary structure. MS2 fusion proteins can leak into 
the cytoplasm during cell death and nuclear disintegration, therefore, keeping cells alive 
is an important consideration. However, the photoactivatable GFP fused MS2 construct 
was created to circumvent this potential problem. By activating in the nucleus only, 
background fluorescence is eliminated. The second issue, the retention of retroviral RNA 
in the nucleus is a more complicated problem. However, we have already established the 
efficient export of the over-expression reporter RNAs during robust polII-MS2-YFP 
expression. A final potential limitation is that the RNA stem loops must be artificially 
engineered into the RNA of interest which may cause unforeseen artifacts in RNA 
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behavior. Nevertheless, based on the data presented here, the use of this system to study 
HIV-1 genomic RNA trafficking will provide invaluable insights into this aspect of virus 
biology. 
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CHAPTER VI 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
HIV-1 genomic RNA performs diverse and important functions during the virus 
life cycle. Some of these benefit the virus, while others inadvertently benefit the host. 
Interestingly, unrelated cellular RNA can perform many functions performed by genomic 
viral RNA, because for many functions specific viral sequences are not required. As a 
result, the study of processes that require RNA (either viral or unrelated) have been 
hindered by the ubiquitous nature of cellular RNA during virus assembly. One potential 
viral RNA-independent function is the incorporation of a particular cellular RNA-binding 
protein into virus particles. This cellular protein, APOBEC3G, exhibits potent anti-viral 
properties that are dependent upon its ability to be packaged into virus particles. The 
specific mechanism of APOBEC3G packaging into virus particles was of great interest to 
us given the possible involvement of RNA in this phenomenon. Consequently, the overall 
goal of this project was the study of RNA involvement in HIV assembly, but specifically, 
to determine the extent of RNA involvement in the packaging of APOBEC3G into virus 
particles. 
Our initial studies determined that A3G is packaged into Gag virus-like particles, 
proving that Gag is responsible for A3G packaging (Figure 5). Furthermore, using a GST 
co-sedimentation assay I showed that A3G from cell lysates interacted with NC but only 
in the presence of RNA (Figure 10). I was surprised to discover, however, that the NC 
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region responsible for causing A3G packaging was the basic linker region and not the N-
terminal I domain (Figure 7). Therefore, to confirm these findings, we purified cell 
membranes and used fluorometry to quantitatively determine that the NC basic linker 
region was also responsible for causing a redistribution of A3G to cellular membranes 
(Figure 9). To explore the hypothesis that RNA binding was the underlying mechanism 
governing A3G packaging I examined the RNA content of these mutant Gag particles. 
My data confirmed that constructs containing the basic linker region also packaged 
significantly increased amounts of RNA (Figure 8A). The importance of the basic linker 
region of NC in causing the packaging of both RNA and A3G indicate that they may be 
packaged together as part of a multimeric complex. 
The intermolecular relationship of A3G molecules bound to RNA was examined 
in particles using a FRET assay. I first established that both whole cells and cell lysates 
showed the presence of multimeric A3G complexes that could be disrupted with the 
application of RNAse. I next applied FRET to A3G molecules contained within virus-like 
particles, demonstrating that A3G is packaged into Gag VLPs as a multimeric A3G-RNA 
complex (Figure 13E-F). Finally, I attempted to use the FRET assay to detect direct Gag-
A3G interactions by co-expressing Gag-CFP and A3G-YFP in 293T cells. However, the 
examination of both cells and particles yielded no detectable Gag-A3G interaction by 
FRET (Figure 14). Taken together, these studies demonstrate that multimeric A3G 
complexes, containing RNA, are associated indirectly with Gag through an RNA 
interaction. 
I next wanted to observe the subcellular distribution of multimeric A3G 
complexes during the process of VLP production. Using fluorescent microscopic analysis 
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I first identified cells with prominent plasma membrane Gag-CFP patterns that had 
colocalization with A3G-YFP at the plasma membrane (Figure 15C-F). Next, using the 
FRET spectral analysis technique of acceptor photobleaching, I determined that A3G 
located in the cytoplasm was either monomeric or dimeric, while A3G located in P-Body 
structures was multimeric (Figure 16). In a complementary technique, FRET images of 
A3G were acquired using specific emission filters and digital image correction. Images of 
A3G expression without Gag using this assay also showed A3G FRET exclusively in P-
Bodies, confirming our earlier results. However, co-expression of Gag in these cells 
caused a visible redistribution of A3G complexes to the plasma membrane in several 
cells that we observed (Figure 17). These data suggest that Gag causes the redistribution 
of A3G complexes to the plasma membrane and into particles during Gag expression as a 
result of an RNA mediated association of A3G complexes with the basic linker region 
NC. 
Finally, to explore other roles that viral RNA may play during HIV infection, we 
have proposed the development of a method to observe genomic HIV RNA in cells. To 
this end, we developed and characterized several tools to accomplish this task. 
Essentially, viral and cellular reporter RNA were engineered to contain binding sites for 
the bacteriophage MS2 coat protein. The MS2 coat protein was then fused to fluorescent 
proteins and an NLS element. Co-transfection of this two-plasmid system allowed us to 
observe the export of reporter RNA molecules into the cytoplasm (Figure 20). This work 
lays the foundation for a system that can eventually become a powerful tool for the study 
of retroviral RNA functions during HIV assembly. 
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RNA Involvement In A3G Packaging 
 The ability to bind and edit RNA is a surprisingly ubiquitous ability present in 
many different species. In bacteria, cytidine to uridine deamination serves mainly a 
metabolic function; however, genera ranging from trypanosomes to plants use this 
technique in addition to other base changes, insertion of bases, and deletion of bases to 
extensively change the information content of their mRNAs (5, 8, 93, 111). In many 
plants, cytidine deaminations are sequence specific edits that are especially pronounced 
in the correction of mitochondria and chloroplast mRNA sequences (38, 90, 102, 128, 
172). Interestingly, the use of this type of editing to create mRNA information appears to 
be much less prevalent in vertebrates. Nevertheless, Cytidine to Uridine editing is 
responsible for creating the transfer RNA for glycine in marsupials and the mRNA for 
apolipoprotein B in mammals (25, 109, 158, 183). In addition, a related type of editing, 
adenosine to inosine editing, has been found to occur in the pre-mRNA of ion channels, 
neurotransmitter receptors, and transfer RNA (20, 82, 139, 156). Recently, the discovery 
was made that a specific cytidine deaminase enzyme, activation-induced cytidine 
deaminase (AID), was responsible for causing widespread hypermuation of somatic B 
cell DNA during antibody maturation and class switching in vertebrates (145, 146, 161). 
This manifestation of permanent, non-sequence specific, and prolific changes to the 
genetic code is in contrast to previously described cytidine deaminase enzymes which 
conduct a limited number of sequences specific changes to relatively temporary RNA 
molecules. In a second drastic paradigm shift in our understanding of the roles that 
Cytidine to Uridine editing plays in biology, it was discovered that the APOBEC3 
proteins lethally hypermutate the genetic cDNA of invading retroviruses (176). The 
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studies in this thesis help to demonstrate the unique and interesting role that RNA binding 
plays in the targeting of antiviral activity towards retroviral genomes. 
APOBEC3G, and subsequently 3F, are the first proteins described that 
deliberately induce genetic mutation in a parasite as an effector mechanism of the innate 
immune system. These fascinating proteins are reminiscent of bacterial innate defense 
proteins called restriction modification systems (RM), which defend bacterial cells by 
targeting invading bacteriophage DNA for destruction by endonuclease activity. Two 
important characteristics of both of these innate immune systems are the method by 
which self and non-self nucleic acids are differentiated, and the effector mechanisms that 
mediate destruction of the pathogen. For RM systems self-DNA is methylated, therefore, 
restriction is only performed on non-methylated viral DNA. In contrast, the targeting 
system that enables APOBEC3 enzymes to differentiate between self-DNA and retroviral 
DNA was not known when these studies were initiated. In this thesis I show that A3G is 
targeted to cellular RNA molecules. However, several studies have shown that A3G only 
lethally mutates ssDNA that is produced using these RNA as a template. Since DNA is 
never produced from cellular RNA molecules A3G is harmless towards cellular nucleic 
acids. A3G is, however, uniquely targeted towards the retroviral genome whose RNA is 
converted to ssDNA soon after infection of a cell during reverse transcription. This 
process would require the A3G molecules to travel with viral RNA into the virus particles 
and eventually into the target cell cytoplasm where reverse transcription occurs. In fact, 
this provides an explanation for why A3G must become incorporated into virus particles 
to function, a major question in the field. Therefore, the studies presented in this thesis 
help to explain how the RNA binding properties of A3G help target its mutagenesis 
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specifically to retroviral DNA, and as a result explain how and why A3G must become 
incorporated into virus particles to function correctly. While the mechanisms of innate 
immunity described here for A3G represent a deviation from the traditional context of 
cytidine deaminase enzymes as creators of temporary mRNA information, this deviation 
has opened up a fascinating and unexpected field of research in the role of these 
hypermutation enzymes as a type of mammalian innate immunity against retroviruses.  
The retroviral RNA genome is believed to also function as a catalyst for the 
assembly of retroviral particles. Several assembly functions, believed to be mediated by 
RNA, have been mapped to two interaction (or “I”) domains located within the NC 
region of Gag (14). Basic residues within the N-terminal I domain are sufficient for 
causing Gag-Gag multimerization, Gag-membrane binding, and the formation of particles 
of proper retroviral density (164, 165). In light of these preceding studies I was surprised 
to discover that the NC region that was critical for causing A3G packaging required the 
inclusion of the basic linker region but not the N-terminal I domain acting alone. This 
was also true for the RNA content of particles. In addition, molecules packaged into 
VLPs must first travel to the plasma membrane, therefore, I confirmed that the NC basic 
linker region was also responsible for causing a redistribution of A3G to cellular 
membrane. Although the basic linker region does not overlap with the N-terminal I 
domain, it is part of the second I domain and contains 4 basic residues that are critical for 
RNA binding (14, 29, 43, 157, 170). Further studies, however, will have to be conducted 
to determine if the basic linker region can recruit A3G in isolation, without the presence 
of the N-terminal sequences. 
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Many authors now agree that mounting evidence affirms that the presence of 
RNA is critical for A3G recruitment into particles by Gag. This mechanism makes sense 
in light of the fact that both A3G and NC are RNA binding proteins. The studies 
presented in this thesis have emphasized this point by showing that the level of RNA 
recruited into virus-like particles correlates closely with the amount of A3G found in 
those particles. This novel finding has advanced the field not only by determining the 
region of Gag needed for maximal RNA binding but also the region of Gag necessary for 
efficient A3G packaging into particles. This approach was necessary because the reliable 
separation of the specific roles played by NC in comparison to RNA during A3G 
recruitment was proving to be challenging to dissect by biochemical methods. Any 
production of Gag or A3G contained ubiquitous amounts of RNA, confounding the 
results. Furthermore, the treatment of these preparations with RNAse produced 
conflicting reports by different authors. Therefore, this experimental approach provided a 
way to determine the relative contribution of RNA to A3G recruitment without having to 
physically separate RNA from NC. This approach proved to be successful method to 
evaluate RNA contribution and complemented the data produced from biochemical 
experiments. Ultimately, however, fine structural determinations may be required to 
determine for certain whether some A3G atoms do in fact interact directly with NC 
atoms. However, overall these data suggest that the NC basic linker region binds to large 
amounts of RNA, which then function to recruit A3G into particles. 
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The Structure of APOBEC3G Complexes 
 The structure of a protein complex often plays a critical role in its function. For 
example, the HIV Rev protein must form a homo-multimeric complex in order to cause 
the efficient export of HIV genomic RNA from the nucleus, presumably through the 
action of multiple cooperative nuclear export signals (129, 130). Studies have shown that 
an initial binding event between a Rev monomer and the high affinity RRE RNA binding 
site occurs in low Rev concentrations. As the late phase of virus replication approaches 
and Rev accumulates in the nucleus, additional Rev molecules are able bind to low 
affinity non-specific sites on the RNA by multimerizing with the initial Rev monomer. In 
this manner, genomic HIV export is regulated by Rev multimerization which is in turn 
regulated by Rev concentration (41, 108). Rev and A3G proteins share similarities in that 
they both bind to RNA and they both form homo-multimers. The exact function that 
multimerization serves in the antiviral activities of A3G is unclear. Perhaps A3G 
multimerization enhances the RNA binding avidity of the complex compared with A3G 
monomers, and as a result, increasing its packaging efficiency. Although the studies 
presented here did not address this question of the nature in which multimerization 
facilitates A3G function, future studies will certainly explore this question. Nevertheless, 
due to the significance that A3G structure may play in its function I undertook the first 
step, a careful study to determine if A3G is packaged into virus particles as a multimeric 
complex. 
 A major question that the studies in this thesis have attempted to answer is: What 
structure do A3G molecules assume during the course of their antiviral activities? Several 
lines of evidence have indicated that nuclease treated A3G molecules extracted from cells 
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lysates results in either monomeric forms or head-to-head dimers that are undetectable by 
FRET. This suggests the possibility that A3G dimers may be the result of an initial RNA-
independent A3G-A3G interaction. These dimers then appear to form higher order 
tetrameric or possibly hexameric structures on RNA substrates, visible by FRET (27, 
190). Some authors have proposed that there is sequence specificity to A3G binding, 
however, no conclusive evidence beyond the clear preference for poly U and T sequences 
has been demonstrated (106). Structurally, Gag appears to associate loosely with A3G 
complexes through a common RNA strand like beads on a string. Thus, allowing its 
separation from A3G complexes by nuclease treatment, and the absence of a detectable 
FRET interaction between Gag and A3G. Therefore, so-called low molecular weight 
(LMW) A3G probably consists of A3G dimers that are “active” due to their availability 
to bind viral RNA, whereas the so-called high molecular weight (HMW) A3G consists of 
multimeric A3G that is already in complex with RNA and thus unavailable to engage 
viral RNA. This explains why in vitro studies indicate that HMW A3G can be activated 
by nuclease treatment (27, 118). However, it is clear that in the process of viral restriction 
by A3G, LMW forms must first condense onto virally packaged RNA to create HMW 
forms which become packaged into particles. Therefore, it seems evident that it is the 
HMW forms which are active against HIV when they are bound to HIV RNA within 
particles. The timing and location of A3G complex formation and dissolution during the 
HIV life cycle is a fascinating area for future studies. It is important to note that the 
presence and possible functions of dimeric (LMW) A3G in viral particles has not been 
determined. This can be investigated using HPLC separation of viral components similar 
to the methods used by Chiu et al. on cell lysates (27). 
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The Intracellular Trafficking of APOBEC3G 
 The intracellular trafficking of a protein is integral to its function in many ways. 
Trafficking can determine such properties as which substrates an enzymatic protein 
works on, the timing of when a protein is activated depending on its subcellular location, 
or how a protein’s function is influenced by changes in the cellular trafficking patterns. 
The basic biology of several cytidine deaminases have been illuminated by an 
understanding of their subcellular localization and trafficking. For instance, the AID 
protein which functions as a mutator of somatic B cell DNA can cause a general mutator 
phenotype leading to the development of lymphoma when its activity is unregulated. 
Therefore, AID contains both a strong C-terminal nuclear export signal (NES) and a 
weak N-terminal nuclear localization signal (NLS). This leads to a predominantly 
cytoplasmic localization, thereby protecting cellular DNA from mutation. However, upon 
the initiation of somatic hypermutation AID relocalizes to the nucleus, possibly by 
disabling the NES or activating the NLS, and leading to mutation of only the correct 
segment of DNA. In this fashion, AID trafficking events are critical to the biology of 
protein function. The experiments described in this thesis indicate that the trafficking of 
A3G is also just as critical to its function. 
 In the absence of Gag expression A3G proteins are found predominantly in two 
locations, diffuse cytoplasmic populations and collections of A3G in mRNA processing 
body (p-body) structures. A third compartment, called stress granules, has been identified 
in which A3G shuttles to during cellular stress, however, it’s significance during HIV 
infection has not been conclusively established. If A3G found in P-bodies is multimeric 
while A3G found diffusely in the cytoplasm is monomeric or dimeric, from which pool 
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of A3G is virally encapsidated forms recruited? Although this question is not directly 
answered by experiments presented here, it is tempting to speculate on this question 
based on what is known about the relationship between A3G structure and function. 
Cytoplasmic A3G found in the monomeric or dimeric form is not in complex with RNA 
and therefore is an “active” form that can attach itself to Gag-RNA complexes trafficking 
to the plasma membrane. This hypothesis fits with the observation an abundance of 
LMW A3G expression in a cell causes an inhibition of HIV replication. Nevertheless, 
this question represents another fascinating area for further research. This line of research 
will certainly benefit from microscopic techniques designed to activate and track specific 
subpopulations of tagged molecules such as the photoactivatable GFP system. 
 The existence of A3G subpopulations in the cell suggests that cellular trafficking 
may be a method of A3G regulation by the cell. In fact, future research may illuminate 
currently unknown aspects of A3G biology by studying the cellular mechanisms that 
govern movement of A3G between different cellular compartments. However, until such 
definite data is available, it is tempting to speculate on this subject based on what is 
known. Greene and colleagues have made the observation that HMW A3G (consistent 
with RNA bound multimeric A3G found in P-bodies) does not readily inhibit HIV 
replication suggesting that its ability to release one strand of (cellular) RNA and engage 
another (viral) is limited (27, 118). However, Kozak and colleagues suggest that A3G-
mRNA complexes can shuttle between protein synthesis polysomes and stress granules 
(117). Nevertheless, it seems plausible that the cell can direct A3G-RNA complexes to 
different cellular locations. It is also a reasonable hypothesis that the cellular proteins and 
mechanisms involved in these processes may also be involved in the trafficking of A3G 
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into retroviral particles. Among the questions to be answered by this active area of 
investigation are whether or not there is equilibrium of A3G between various cellular 
compartments that is perturbed by HIV infection of a cell. What structure do A3G 
complexes take within the various cellular compartments and how is this important to 
A3G function? More specifically, can the multimeric forms of A3G return to their 
dimeric/monomeric forms or subcellular locations? The experiments in this thesis have 
framed these questions by outlining the structure in which A3G exists in several 
subcellular locations. 
 
Model of APOBEC3G Packaging 
 My research has addressed many gaps in our understanding of the functions for 
retroviral RNA. We have developed a robust model for RNA functions in A3G packaging 
into particles, summarized in Figure 21. In our model, A3G normally exists in two main 
cellular compartments, a diffusely cytoplasmic dimer or monomer undetectable by FRET, 
and a multimer detectable by FRET in structures consistent with mRNA processing 
bodies (P-bodies). Gag forms multimers on cellular membranes using RNA as a catalyst 
and traffics to the plasma membrane. Dimeric A3G from the diffuse cytoplasmic pool 
multimerizes onto the RNA that is traveling with Gag. Finally, Gag arrives at the plasma 
membrane bringing both RNA and A3G with it into virus particles. In summary, our 
results provide strong support for the importance of RNA in mediating the incorporation 
of multimeric forms of APOBEC3G into virions or VLPs. This incorporation is 
dependent upon regions of Gag within NC that allow efficient RNA incorporation, 
especially the basic linker region. 
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Figure 21. Model of APOBEC3G recruitment into virus particles. APOBEC3G (A3G) 
exists as diffuse cytoplasmic dimers and also as multimers in cytoplasmic 
accumulations. Step 1: Gag multimerizes on cellular membranes using RNA as a 
catalyst, Step 2: A3G multimerizes on RNA that is bound to Gag multimers. Step 3: 
Gag traffics to the plasma membrane taking the RNA and A3G with it. Step 4: 
Particles form containing A3G multimers. 
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Future Directions in Therapeutics 
 The experiments in this thesis provide basic information about mechanisms 
governing A3G packaging that can be used to design novel anti-retroviral therapies. I 
have learned that the same mechanisms responsible for recruiting viral genome into the 
particle are also responsible for recruiting A3G. As a result, any attempt by the virus to 
disrupt A3G packaging by interfering with these mechanisms would also result in a 
disruption of viral genomic packaging. This helps to explain why the virus would need to 
evolve a defense mechanism centered around the reduction of A3G expression levels. 
The theoretical interventions described in this section fall into two categories: 1) 
increasing A3G expression levels, 2) developing ways to concentrate any remaining A3G 
onto HIV genomic RNA, the latter being most specific to the studies presented in this 
thesis. 
Any intervention that overexpresses or restores the expression levels of the 
circulating pool of diffuse cytoplasmic A3G may promote uptake of A3G into virus 
particles and achieve a therapeutic effect. It is tempting to speculate on how this could be 
accomplished. The simplest way to do this would be to induce increased expression of 
A3G. The experiments in Figure 6 demonstrate that the effect of the Vif protein can be 
saturated by overexpression of A3G. Therefore, a pharmaceutical compound that 
increases expression of A3G without increasing CD4+ cell activation could help to limit 
virus replication. Another way to approach this strategy would be to disrupt the 
interaction between A3G and Vif. Essentially, a small molecule that binds to either A3G 
or Vif could inhibit this interaction and prevent A3G polyubiquitination and degradation. 
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This is approach provides the most direct route to a pharmaceutical solution and is being 
pursued actively by several investigators (138). 
Several key studies in this thesis have shown that A3G exists in at least two forms 
in at least two different cellular compartments. The dimeric/monomeric state appears to 
be the state able to engage retroviral RNA. Therefore, one way to increase the functional 
A3G in the cell would be to develop therapies designed to convert multimeric A3G found 
in accumulations of A3G into to cytoplasmic dimeric/monomeric A3G. Although RNAse 
treatment has been shown to liberate and activate multimeric A3G into the 
dimeric/monomeric form, it is likely that the potential toxicity from over-expression of a 
cytoplasmic RNAse would be quite toxic all protein synthesis. Nevertheless, future 
studies of A3G trafficking and multimerization should reveal additional molecules both 
cellular and viral that are involved in the regulation of these states and can therefore be 
used as targets for therapeutic modalities. For instance, these modalities could be targeted 
to inhibit A3G trafficking to P-bodies or encouraging the liberation of A3G from P-
bodies. This could potentially initiate a redistribute of large amounts of A3G stored in p-
bodies as multimers back into the cytoplasm as monomers or dimers, causing a large 
infusion of A3G into all virus particles produced in a patient and terminating viral 
replication. 
The second general category of therapeutics relates to designing strategies to 
enhance the targeting of A3G molecules specifically to viral RNA. This category 
represents a greater challenge since most small molecule pharmaceuticals are designed to 
inhibit or mimic biological molecules rather than promote the interaction of two specific 
proteins. Nevertheless, technical difficulties notwithstanding, one way to do this would 
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be by making a Tat-A3G fusion protein. This protein could be administered 
intravenously, and would enter CD4+ cells due to the membrane penetrating properties of 
the Tat domain. It could then preferentially bind to retroviral RNA containing the 5’ Tar 
stem loop structure. In fact, the retroviral genome has several RNA stem-loop structures 
that could be used as targeting locations. These include the Psi packaging signal, the TAR 
element that promotes mRNA elongation, and the Rev Response Element (RRE) that 
promotes the export of genomic retroviral RNA from the nucleus. Fusion proteins of 
A3G with NC (which binds to Psi), Tat (mentioned above), or Rev (which binds to the 
RRE) could all be used to target any remaining A3G molecules to HIV genomic RNA. 
The delivery of a therapy based on a protein to human tissue is a very serious technical 
problem that has not been solved yet to a high degree of satisfaction yet. However, 
solutions that have been proposed and remain feasible possibilities include attaching cell-
penetrating peptides to the A3G-fusion proteins (such as Tat-A3G, Tat-A3G-NC, Tat-
A3G-Rev), conducting gene therapy with adenovirus or another retrovirus, or delivery 
using a fusion capable virus-like particle or nano-container that is filled with the protein 
of interest. It is of note that the target tissue, CD4+ T cells, conveniently circulates in the 
blood, which enhances their accessibility to such therapies. 
As a final idea, current anti-retrovirals such as protease inhibitors could be 
conjugated to RNA binding molecules. This might help target these therapies into virus 
particles in a powerful and effective manner. Although each of these strategies would 
require extensive research and development, the basic biology of A3G packaging 
described in this thesis provides the framework for these future studies. 
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 In conclusion, this thesis has provided insights into the role that RNA plays in 
mediating the packaging of APOBEC3G into HIV particles via the NC region of Gag. 
This demonstrates that therapeutics targeted into virus particles through RNA binding 
could be extremely effective at limiting virus replication. In this way, our data paves the 
way for the future development of novel anti-retroviral therapies that target viral RNA.
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APPENDIX A 
 
MA-DELETED HIV-1 GAG EXPRESSION CONSTRUCTS 
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MA-Deleted HIV-1 Gag Expression Constructs 
 
Introduction 
One of the first projects I worked on in the Spearman lab involved determining 
the role of the Adapter Protein 3 complex (AP-3) complex in Gag trafficking. 
Specifically we asked the following questions: 1) What subdomain of Gag does AP-3 
bind to, 2) Where in the cell does the AP-3 complex traffic Gag to, 3) Does AP-3 
complex trafficking of Gag have functional implications for particle assembly? Initial 
yeast two-hybrid experiments, GST co-sedimentation studies, and co-
immunoprecipitation studies showed that the Matrix (MA) sub-domain of the HIV-1 Gag 
protein was responsible for binding to the AP-3. Confocal fluorescence microscopy and 
immuno-labeled electron microscopy was used to show that the AP-3 complex facilitated 
Gag trafficking to the multi-vesicular body (MVB), type of late endosome used for 
sorting. We then determined that this interaction and subsequent trafficking to the MVB 
was functional step in particle assembly by showing that Gag-Pol expression constructs 
experienced significant impairment of particle output in cells expressing a dominant 
negative fragment of the AP-3 complex termed AP3D-5’. It became clear that a Gag 
molecule able to bypass AP-3 trafficking and go directly to the plasma membrane would 
serve as an excellent negative control for functional studies of particle release involving 
siRNA depletion of the AP-3 complex. The Src∆MAGag construct was made as just such 
a control given that the V-Src myristylation sequence is able to target proteins to the 
plasma membrane (6, 196). Therefore, Src∆MAGag was used to show that siRNA 
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depletion of the AP-3 complex severely impaired release of pNL4-3 but not Src∆MAGag 
particles in HeLa cells.  
 
Materials and Methods 
 
Plasmid Construction 
The Gag coding sequences for all constructs were derived from the codon-
optimized version of HXB2 Gag in expression plasmid pVRC3900 (104). PCR cloning 
was used to amplify the CA-p6 region of the gag gene from the pVRC3900 vector with 
the first 9 amino acids of the V-Src oncogene, including the myristylation sequence, 
added prior to the start of CA. A HindIII site was added prior to the 5’ ATG and a BamHI 
site was added at the 3’ end and for C-Terminal fluorescent fusion constructs the gag stop 
codon was omitted. The amplified gag gene was then ligated into pcDNA3.1(+), pEGFP-
N3 and pEYFP-N3 by digestion of the BamHI and HindIII sites located within the 
multiple cloning regions. The forward oligonucleotide used in PCR amplifications for all 
constructs was AACAAGCTTGCCACCATGGGCTCCTCCAAGT 
CCAAGCCCAAGCCCATCGTGCAGAACATC-(F). Reverse oligonucleotides used in 
PCR amplifications were CGGGATCCTTATTGTGACGAGGGGTC-(R) 
(Src∆MAGag), GGGGATCCTTGTGACGAGGGGTCGCTG-(R) (Src∆MAGag-GFP 
and Src∆MAGag-YFP). A schematic diagram of the Gag expression constructs employed 
in this study is shown in Fig. 22. 
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Figure 22. Gag constructs lacking the MA region. Schematic representation of (A) 
Pr55Gag, (B) Src∆MAGag, (C) Src∆MAGag-GFP, (D) Src∆MAGag-YFP. 
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Cell lines and transfections 
The human kidney cell line 293T was maintained in Dulbecco’s modified Eagle 
medium with 10% fetal bovine serum and antibiotics at 37°C in 5% CO2, and grown in 
100-cm2 tissue culture dishes. Transfections were performed by either the calcium 
phosphate-BBS transfection method or with Lipofectamine 2000 (Invitrogen, Carlsbad, 
Calif.), with 10 µg of total plasmid DNA unless otherwise stated. 
 
Antibodies and Immunoblotting 
Lysate preparations were analyzed by SDS-polyacrylamide gel electrophoresis 
followed by transfer to nitrocellulose membrane and immunoblotting. Gag was blotted 
with the monoclonal antibody CA-183, and GFP antisera was obtained from Santa Cruz 
(Santa Cruz, California). Secondary fluorescent conjugated antibodies for detection on 
the LiCor Odyssey were obtained from LI-COR, Inc. (Lincoln, Nebraska). 
 
Results 
 293T cells were transfected with each expression construct and cell lysates were 
made by detergent lysis. To verify that each matrix deleted Gag expression construct was 
correct, immunoblots were performed on the cell lysates and the approximate size of each 
protein was compared to the predicted size. In the case of the GFP and YFP fusion 
proteins, immunobloting simultaneously with both the Gag and GFP antibodies indicated 
the size of the full-length protein by the band that showed up in the same location on both 
blots. Gag (55 kDa) and Src∆MAGag (38 kDa) were detected at the correct sizes upon 
immunoblotting with a capsid (CA) specific antibody (Fig. 23A). GFP (28 kDa) was 
 128 
 
Figure 23. Expression of Gag constructs lacking the MA region. 293T cells were 
transfected with the indicated constructs. Following lysis, proteins were separated 
using SDS PAGE and blotted using (A) a Gag specific antibody (arrows indicate 55 
kDa, 38 kDa) and (B) both GFP and Gag specific antibodies (arrows indicate 66 kDa, 
28 kDa). 
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detected at the correct size upon immunoblot with a GFP specific antibody, while 
Src∆MAGag-GFP (66 kDa) and Src∆MAGag-YFP (66 kDa) were also detected at the 
corrected size but in both the Gag specific and GFP specific immunoblots (Fig 23B). This 
confirms the correct expression of these Gag constructs. 
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APOBEC3G Expression Constructs 
 
Introduction 
 Chapters II through IV focus on APOBEC3G packaging determinants and the 
multimeric nature of packaged APOBEC3G. During the course of these studies, several 
APOBEC3G expression constructs were created but were not used in publication. These 
include recombinant bacterial and baculoviral APOBEC3G expression vectors whose 
creation and characterization is presented here. 
 
Materials and Methods 
 
Plasmids Construction 
 PCR cloning was used to amplify the APOBEC3G gene from the CEM15 plasmid 
(obtained from Michael Malim) by placing an EcoRI site prior to the 5’ ATG and an 
XhoI site at the 3’ end. The amplified APOBEC3G gene was then ligated into pCMV-HA 
to yield a new construct designated HA-A3G. The oligonucleotides used in the PCR 
amplifications were GGAATTCGGATGAAGCCTCACTTCAGA-(F) and 
CCGCTCGAGTCAGTTTTCCTGATTCTG-(R). 
 PCR cloning was used to amplify the HA-APOBEC3G sequence from the HA-
A3G plasmid by placing an SmaI site prior to the 5’ ATG and an XhoI site at the 3’ end. 
The amplified APOBEC3G gene was then ligated into the bacterial expression vector 
pGEX-6P-1 to yield a new construct designated GST-HA-A3G. The oligonucleotides 
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used in the PCR amplifications were TACCCCCGGGGATGTACCCATACGAT-(F) and 
CCGCTCGAGTCAGTTTTCCTGATTCTG-(R). 
 PCR was used to amplify the APOBEC3G sequence from the CEM15 plasmid by 
placing an EcoRI site at the 3’ end using the following oligonucleotides 
CTGGAAGTTCTGTTCCAGGGGCCCATGAAGCCTCAC-(F) and 
GGAATTCTCAGTTTTCCTGATTCTG-(R). PCR was then used to amplify the GST 
sequence from the pGEX-6P-1 plasmid by placing an EcoRI site prior to the 5’ ATG 
using the following oligonucleotides CGAATTCATGTCCCCTATACTA-(F) and 
GAACAGAACTTCCAGATCCGATTTTGG-(R). These products were joined to create 
GST-A3G by overlap extension PCR, and ligated into the baculovirus transfer vector 
pVL1392 to create the construct GST-A3G1392. 
 
Expression and purification 
GST-HA-A3G was expressed in E. Coli and purified from bacterial cell lysates 
using glutathione agarose beads. HA-A3G was cleaved off the beads using 
PrescissionProtease and serial dilutions were analyzed by SDS polyacrylamide gel 
electrophoresis (PAGE) followed by immunoblotting with an APOBEC3G specific 
antibody Warner C. Greene through the NIH AIDS Research and Reference Reagent 
Program (181). A GST-A3G expressing baculovirus was made by genetic recombination 
after cotransfection of insect SF9 cells with GST-A3G1392 and BaculoGold Bright 
linearized baculovirus DNA. Virus was amplified and titerred using GFP fluorescence. 
This virus was then used to infect SF9 insect cells, and GST-A3G was purified and 
analyzed from insect cell lysates as described above. 
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Results 
 HA-A3G was purified from bacterial cell lysates and separated by SDS PAGE 
and immunoblotted using A3G antisera. Correct expression was verified by the correct 
size (50 kDa) of serial dilutions shown in Figure 24A. A3G was purified from bacterial 
cell lysates and separated by SDS PAGE and immunoblotted using A3G antisera. Correct 
expression was verified by the correct size (50 kDa) of serial dilutions shown in Figure 
24B.   
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Figure 24. APOBEC3G expression constructs. (A) E. Coli bacteria were induced to 
express GST-HA-APOBEC3G. Following lysis, GST purification, and preatease 
cleavage, immunoblot with an APOBEC3G (A3G) specific antibody revealed 
correct expression of A3G. (B) Insect cells were infected with a GST-APOBEC3G 
expressing baculovirus. Following lysis, GST purification, and protease clavage, 
immunoblot with an A3G specific antibody revealed correct expression of A3G. 
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The Human Metapneumovirus Nucleoprotein and Phosphoprotein 
Interact by FRET Analysis 
 
Introduction 
 Human metapneumovirus (hMPV) is a recently discovered paramyxovirus of the 
Pneumovirinae subfamily, which also includes avian pneumovirus and respiratory 
syncytial virus (RSV). hMPV is an important cause of respiratory disease worldwide. To 
understand early events in hMPV replication, the cDNA encoding the hMPV 
nucleoprotein (N), phosphoprotein (P), was cloned from cells infected with the genotype 
A1 hMPV wild-type strain TN/96/12. We used the Förster resonance energy transfer 
(FRET) technique to show that hMPV N interacts with hMPV P. 
 
Materials and Methods 
FRET analysis by scanning cuvette fluorometry. One 10-cm2 dish of nearly 
confluent 293T cells were transfected for each experimental condition using 
Lipofectamine 2000 (Invitrogen, Carlsbad, Calif.). Cells were harvested for analysis 24 h 
following transfection and washed in phosphate-buffered saline and kept at 4°C. Whole 
cells were then analyzed by fluorometry in a PTI T-format scanning cuvette 
spectrofluorometer (Photon Tehnology international, Lawrenceville, N.J.). Samples were 
excited at 433 nm, and a resulting emission scan ranging from 450 to 550 nm was 
obtained. Samples were exited at 514 nm, with a resulting emission scan of 526 to 600 
nm, for analysis of YFP emission to compare the relative amount of YFP present. 
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Results 
 The Venus-P and Cerulean-N fusion proteins were co-expressed in HEK 293T 
cells. As a negative control, each was also co-expressed with either CFP or YFP, 
respectively. The emission spectrum of whole cells was then obtained in a 
spectrofluorometer using an excitation wavelength of 433 nm. Cells expressing Venus-P 
and Cerulean-N (Fig. 25A, red squares), exhibited a curve representative of efficient 
fluorescence energy transfer. However, analysis of cells co-expressing Venus-P with 
CFP, or Cerulean-N with YFP resulted in CFP emission peaks with no FRET emission 
peak (Fig. 25A, closed circles and closed triangles, respectively). Similar levels of YFP 
emission were obtained upon YFP excitation for each experimental condition, indicating 
that differential protein levels did not account for the differences between negative 
controls and the test molecules (Fig. 25B). We conclude that the N and P proteins interact 
by FRET analysis. The studies presented in this appendix were performed in 
collaboration with Aaron Derdowski in Timothy Peters’ lab. The results are in the 
process of being submitted as a manuscript for publication along with other supporting 
data. 
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Figure 25. Analysis of P and N protein interactions by FRET fluorometry. Whole 
293T cells were analyzed in a scanning cuvette fluorometer as described in 
Materials and Methods. Venus hMPV P-Cerulean hMPV N FRET curve (red 
diamonds) shows a Venus emission peak at 527 nm in cells expressing both 
proteins. Closed circles: Venus hMPV P expressed with CFP control protein. 
Closed triangles: Cerulean hMPV N expressed with YFP control protein.  
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